

05/19/98
USPTO

Please type a plus sign (+) inside this box

Box 5601 A
+
PTO/SB/05 (12/97)

**UTILITY
PATENT
APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 19959Y Total Pages 86
First Named Inventor or Application Identifier
Qingyun Liu et al.
Express Mail Label No. EM230308762US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
1. <input checked="" type="checkbox"/> Fee Transmittal Form <small>(Submit an original, and a duplicate for fee processing)</small>		ACCOMPANYING APPLICATION PARTS <p>7. <input type="checkbox"/> Assignment papers (cover sheet & document(s))</p> <p>8. <input type="checkbox"/> 37 CFR 3.73(b) Statement <small>(when there is an assignee)</small> <input type="checkbox"/> Power of Attorney</p> <p>9. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>10. <input type="checkbox"/> Preliminary Amendment</p> <p>11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small></p> <p>12. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small></p> <p>13. <input checked="" type="checkbox"/> Other: Transmittal fee T10</p> <hr/> <hr/> <hr/> <hr/> <hr/> <hr/>
2. <input checked="" type="checkbox"/> Specification [Total Pages 69]		
3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets 14]		
4. Oath or Declaration [Total Pages 3]		
a. <input checked="" type="checkbox"/> Newly executed (original or copy) <small>(unsigned)</small>		
b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 14 completed)</small>		
[Note Box 5 below]		
i. <input type="checkbox"/> DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).</small>		
5. <input type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked). The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.		
6. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small>		
a. <input checked="" type="checkbox"/> Computer Readable Copy		
b. <input type="checkbox"/> Paper Copy (identical to computer copy)		
c. <input checked="" type="checkbox"/> Statement verifying identity of above copies		
14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input checked="" type="checkbox"/> Continuation-in-part (CIP) of prior application No. 60 / 69141		
15. CORRESPONDENCE ADDRESS		
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		Customer No. 000210 <small>(Insert Customer No. or Attach bar code here)</small>
NAME	J. Mark Hand <i>J. Mark Hand 5/19/98</i>	
ADDRESS	Merck & Co., Inc., P. O. Box 2000	
CITY	STATE	ZIP CODE
COUNTRY	TELEPHONE	FAX

(computer generated form No. U6 - Merck & Co., Inc., 12/97)

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT May 19, 1998

EXPRESS MAIL NO. EM230308762US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, BOX PATENT APPLICATION, WASHINGTON, D.C. 20231.

MAILED BY *Gene Sennet*

DATE *May 19, 1998*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Deposit Acct. 13-2755
MERCK & CO., INC.
Our Case Docket No. 19959Y

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the patent application of Inventor(s):
Qingyun Liu and Fang Chen

For: HUMAN UNCOUPLING PROTEIN 3

For	Number Filed	Number Extra	Rate	Basic Fee \$790
Total Claims	44 - 20 =	24 X	\$22	= 528.00
Independent Claims	12 - 3 =	9 X	\$82	= 738.00
Multiple Dependent Claims		X	\$270	=
* Add this fee if application contains any multiple dependent claims, regardless of number.			TOTAL FILING FEE →	\$2056.00

* Please charge my Deposit Account No. 13-2755 in the amount of \$ 2056.00. The Assistant Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 13-2755.
Duplicate copy of this sheet is enclosed.

Under the provisions of 37 C.F.R. §1.53, this application is being filed without the declaration of each inventor.

Respectfully,



By: J. Mark Hand

Attorney For Applicant(s)Reg. No. 36,545

MERCK & CO., INC.

Patent Dept.

P.O. Box 2000

Rahway, N.J. 07065-0907

(732) 594- 3905Date: May 19, 1998

EXPRESS MAIL CERTIFICATE	
DATE OF DEPOSIT	May 19, 1998
EXPRESS MAIL NO. EM230308762US	
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.	
MAILED BY <u>Jane Samul</u>	DATE <u>May 19, 1998</u>

EXPRESS MAIL EM230308762US
MAY 19, 1998

APPLICATION OF QINGYUN LIU AND FANG CHEN
5 MERCK CASE NO. 19959Y

TITLE OF THE INVENTION
HUMAN UNCOUPLING PROTEIN 3

10
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a non-provisional application of U.S.
Provisional Application Serial No.60/069,141 filed December 9, 1997,
which is a continuation-in-part of U.S. Provisional Application Serial
15 No. 60/047,179, filed May 20, 1997.

STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not applicable.
20

REFERENCE TO MICROFICHE APPENDIX
Not applicable

FIELD OF THE INVENTION
25 The present invention relates to an isolated nucleic acid
molecule (polynucleotide) which encodes a novel human uncoupling
protein, referred to throughout as uncoupling protein 3 (UCP3). The
present invention also relates to recombinant vectors and recombinant
hosts which contain a DNA fragment encoding human UCP3,
30 substantially purified forms of associated human UCP3, human UCP3
mutant proteins, and methods associated with identifying compounds
which modulate energy expenditure and body weight regulation, as well
as affecting diseases such as obesity and diabetes.

35

BACKGROUND OF THE INVENTION

The balancing of energy expenditure and food intake plays a critical role in the control of body weight. Heat generation from uncoupling activity in mitochondria is responsible for a significant portion of energy expenditure, and therefore regulation of uncoupling activities provides a direct target for the treatment of obesity.

It is known that uncoupled mitochondrial respiration in brown adipose tissue (BAT) plays an important role in the regulation of energy balance in rodents.

10 Bouillaud et al. (1986, *J. Biol. Chem.*.. 261(4): 1487-1490) disclose a rat cDNA clone which encodes rat uncoupling protein 1 (UCP1). Rat UCP1 is a mitochondrial inner membrane protein synthesized in the cytosol from a nuclear encoded transcript which is expressed in brown adipose tissue.

15 Bouillaud et al. (1988, *Biochem. Biophys Res. Comm.* 157: 783-792) disclose a genomic clone encoding rat UCP1.

20 Nicholls and Locke (1984, *Physiol. Rev.* 64: 1-64) review UCP1, noting that the rat 32 kD protein forms a proton channel through the mitochondrial inner membrane and is active in uncoupling ATP synthesis from heat production in BAT.

25 Jacobsson et al. (1985, *J. Biol. Chem.* 260: 16250-16254) disclose cDNA clones for mRNA isolated from mouse brown adipose tissue. Mouse *ucp1* mRNA was shown to be induced in brown adipose tissue by exposure to cold.

30 Kozak et al. (1988, *J. Biol. Chem.* 263: 12274-12277) disclose the genomic clone encoding mouse UCP1.

35 Cassard et al. (1990, *J. Cell. Biochem.* 43: 255-264) discloses the genomic clone for human *ucp1*, as well as the deduced amino acid sequence for human UCP1. The authors show that rat and human UCP1 are 79% homologous at both the nucleotide and amino acid level.

UCP1 activity in thermogenesis and uncoupled energy dissipation is limited to brown adipose tissue. Therefore, it is not expected that UCP1 is actively involved in the cause and effect of body weight indications such as obesity and diabetes in vertebrates such as humans, which contain limited amount of brown fat.

Fleury et al. (1997, *Nature Genetics* 15: 269-272) disclose a gene encoding both a mouse and human mitochondrial uncoupling protein, designated mouse UCP2 and human UCP2, respectively. The deduced human amino acid sequence encodes a 33 kD protein which is approximately 95% homologous to the mouse protein at the amino acid level. As with human UCP1, human UCP2 comprises 3 mitochondrial carrier protein motifs and an ATP binding site. The authors show a wide range of tissue specific expression of the human *ucp2* gene, including skeletal muscle, lung, heart, placenta, stomach, as well as immune systems tissue such as spleen, thymus, leukocytes, macrophages and bone marrow. The authors mapped the human *ucp2* gene to chromosome 11, which has been linked to obesity and hyperinsulinaemia in the mouse.

It would be advantageous to identify a gene encoding an additional human uncoupling protein wherein expression is for the most part limited to skeletal muscle. A nucleic acid molecule expressing an additional human uncoupling protein in such a specific manner would be extremely useful in screening for compounds acting as a modulator of obesity and hyperinsulinaemia. Such a compound or compounds will be useful in controlling obesity as well as deleterious indications associated with obesity, such as diabetes. Additionally, such a nucleic acid molecule will be useful in gene therapy applications to overcome the deleterious effects of obesity and obesity-related complications, such as diabetes. The present invention addresses and meets this need.

SUMMARY OF THE INVENTION

The present invention relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel vertebrate uncoupling protein.

The present invention relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel human uncoupling protein.

The present invention also relates to a purified or isolated nucleic acid molecule which encodes a human uncoupling

protein which is predominantly expressed within human skeletal muscle.

A preferred aspect of the present invention is disclosed in Figure 1A-1B and SEQ ID NO:11, a purified human cDNA 5 encoding a novel uncoupling protein, UCP3.

Another specific embodiment of the present invention relates to isolated biologically active fragments or mutants of a nucleic acid molecule encoding human uncoupling protein 3, disclosed herein in Figure 2A-2D, Figure 3 and SEQ ID NO:12. Any 10 such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.

15 The present invention relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel mouse uncoupling protein, as set forth as SEQ ID NO:17.

20 The present invention also relates to a purified or isolated nucleic acid molecule which encodes a mouse uncoupling protein which is predominantly expressed within human skeletal muscle, the expressed protein as set forth in SEQ ID NO:18.

25 The purified nucleic acid molecule of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).

30 The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified mammalian nucleic acid molecules disclosed throughout this specification.

35 The present invention also relates to subcellular membrane fractions of the recombinant host cells (both prokaryotic and eukaryotic as well as both stably and transiently transformed

cells) comprising the nucleic acids of the present invention. These subcellular membrane fractions will comprise UCP3 at levels substantially above wild type levels and hence will be useful in various assays described throughout this specification.

5 The present invention also relates to a substantially purified human uncoupling protein wherein the native form is substantially localized within mitochondria of skeletal muscle.

10 A preferred aspect of the present invention is disclosed in Figure 2 and SEQ ID NO:12, the amino acid sequence of the exemplified human uncoupling protein, hUCP3.

Another preferred aspect of the present invention is disclosed in Figure 7 and SEQ ID NO:18, the amino acid sequence of the exemplified mouse uncoupling protein, mUCP3.

15 The present invention also relates to biologically active fragments and/or mutants of a novel human uncoupling protein, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.

20 The present invention also relates to methods of expressing the UCP proteins or protein fragments disclosed herein, assays employing these human UCPs, cells expressing these UCPs, and compounds identified through the use of these UCPs, including modulators of energy expenditure and body weight regulation, either through direct 25 contact with the mitochondrial uncoupling protein, or a compound which acts in trans to modulate UCP expression. Such modulators identified in this process are useful as therapeutic agents for controlling obesity, diabetes and other related diseases.

30 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1A and Figure 1B show the nucleotide sequence (SEQ ID NO:11) which comprises the full-length cDNA encoding human uncoupling protein 3.

Figure 2A, Figure 2B, Figure 2C and Figure 2D show the translation of the open reading frame (SEQ ID NO:12) of the full-length human uncoupling protein 3 nucleotide sequence.

5 Figure 3 shows the amino acid sequence of human uncoupling protein 3 (SEQ ID NO:12).

Figure 4A, Figure 4B and Figure 4C show Northern blot analysis of human uncoupling protein 3 in human tissue.

10 Figure 5 shows the orientation of vector and gene specific primers used to screen a human fetal brain cDNA library for a full-length human UCP3 cDNA.

Figure 6A and 6B shows the nucleotide sequence (SEQ ID NO:17) of a cDNA which encodes the full-length mouse uncoupling protein 3.

Figure 7 shows the amino acid sequence (SEQ ID NO:18) of the mouse uncoupling protein 3.

15 Figure 8A, Figure 8B and Figure 8C show flow cytometry analysis of mitochondria membrane potential with UCP3 expression in yeast. The *S. cerevisiae* strain W303 containing vector alone (Figure 8A) or UCP3 expression plasmids (Figure 8B and Figure 8C) were stained with the potential sensitive dye, DiOC6 and analyzed by FACS. The X-axis represents the intensity of fluorescence on logarithmic scale while the Y-axis indicates the number of cells. "+gal" indicates that cells were induced with galactose for 5 hours. "-gal" indicates cells were maintained in raffinose media without the induction by galactose. A decrease in fluorescence intensity indicates a reduction in mitochondria membrane potential.

20 Figure 9A and Figure 9B shows the response of UCP3 expression to adenovirus-mediated leptin treatment. Figure 9A shows measurement of weight loss. Y-axis indicates the average weight expressed in percentage of weight relative to the day of injection (Day 0).
25 Figure 9B shows UCP3 mRNA level. Y-axis indicates the relative level of UCP3 mRNA (the average of the Adb-gal and control animals is assigned a value of 1). Standard deviation for each group is as marked. Ad-Leptin: first generation E1-deleted, replication deficient adenoviral vector expressing leptin; HD-leptin: helper-dependent adenoviral vector

expressing leptin; Adb-gal: first generation adenoviral vector expressing β -galactosidase; Control: untreated.

DETAILED DESCRIPTION OF THE INVENTION

5 The present invention relates to isolated nucleic acid and protein forms which represent a vertebrate uncoupling protein, preferably human and mouse forms. The isolated genes and concomitant translation products which make up a portion of the present invention may be used in various ways in the treatment of
10 obesity and other related diseases, including but not limited to diabetes. The uncoupling protein of the present invention is a protein which is translated in the cytosol from a nuclear encoded mRNA transcript. This uncoupling protein is presumably imported into the mitochondrial inner membrane post-translationally.

15 The process of oxidative phosphorylation pumps protons to the outside of the inner membrane of the mitochondria, leading to the generation of a membrane potential across the inner membrane. This membrane potential is then used to drive ATP synthesis. The purified uncoupling proteins of the present invention have the ability to uncouple
20 the protonmotive force associated with oxidative phosphorylation, resulting in the concomitant release of large amounts of energy. It will be within the scope of the present invention to use the herein disclosed nucleic acids to construct recombinant vectors and recombinant host cells wherein the human UCP3 gene is expressed, either stably or
25 transiently. Such transformed recombinant cell lines will be useful in screening for modulators of UCP3 activity, and hence, as effectors of energy expenditure and body weight regulation. The isolated nucleic acid fragments of the present invention will also be useful in gene therapy applications regarding therapeutic treatment of obesity and
30 obesity related indications, including but not limited to diabetes, as well as conditions such as mitochondrial-associated hypermetabolism.

 To this end, the present invention relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel human uncoupling protein.

The present invention also relates to a purified or isolated nucleic acid molecule which encodes a human uncoupling protein which is predominantly expressed within human skeletal muscle.

5 A preferred aspect of the present invention is disclosed in Figure 1 and SEQ ID NO:11, a purified human cDNA encoding a novel uncoupling protein, UCP3, which is as follows:

TCGAACTCAC TCACCTCCCC TCTCACCTCA CTGCCCTCAC CAGCCAGCCT
CTTGTCAAGT GATCAGGCTG TCAACCCAATC TCTCTAGGAT AAGGTTTCAG
10 GTCAGCCTGT GTGTATAAGA CCAGTGCCAA GCCAGAAGCA GCAGAGACAA
CAGTGAATGA CAAGGAGGGG CCATCCAATC CCTGCTGCCA CCTCCTGGGA
TGGAGCCCTA GGGAGCCCT GTGCTGCCCT TGCCGTGGCA GGACTCACAG
CCCCACCGCT GCACTGAAGC CCAGGGCTGT GGAGCAGCTC TCTCCTTGGA
CTCCTCTCGG CCCTAAAGGG ACTGGGCAGA GCCTTCCAGG ACTATGGTTG
15 GACTGAAGCC TTCAGACGTG CCTCCCACCA TGGCTGTGAA GTTCCTGGGG
GCAGGGCACAG CAGCCTGTTT TGCTGACCTC GTTACCTTTC CACTGGACAC
AGCCAAGGTC CGCCTGCAGA TCCAGGGGA GAACCAGGCG GTCCAGACGG
CCCGGCTCGT GCAGTACCGT GGCGTGCTGG GCACCATCCT GACCATGGTG
CGGACTGAGG GTCCCTGCAG CCCCTACAAT GGGCTGGTGG CCGGCCTGCA
20 GCGCCAGATG AGCTTCGCCCT CCATCCGCAT CGGCCTTTAC GACTCCGTCA
AGCAGGTGTA CACCCCCAAA GGCAGGGACA ACTCCAGCCT CACTACCCGG
ATTTTGGCCG GCTGCACCAC AGGAGCCATG GCGGTGACCT GTGCCAGGCC
CACAGATGTG GTGAAGGTCC GATTTCAGGC CAGCATAACAC CTCGGGCCAT
CCAGGAGCGA CAGAAAATAC AGCGGGACTA TGGACGCCTA CAGAACCATC
25 GCCAGGGAGG AAGGAGTCAG GGGCCTGTGG AAAGGAACCTT TGCCCAACAT
CATGAGGAAT GCTATCGTCA ACTGTGCTGA GGTGGTGACC TACGACATCC
TCAAGGAGAA GCTGCTGGAC TATCACCTGC TCACTGACAA CTTCCCTGTC
CACTTTGTCT CTGCCTTGG AGCCGGCTTC TGTGCCACAG TGGTGGCCTC
CCCGGTGGAC GTGGTGAAGA CCCGGTATAT GAACTCACCT CCAGGCCAGT
30 ACTTCAGCCC CCTCGACTGT ATGATAAAGA TGGTGGCCCA GGAGGGCCCC
ACAGCCTTCT ACAAGGGATT TACACCCCTCC TTTTTGCGTT TGGGATCCTG
GAACGTGGTG ATGTTCGTAA CCTATGAGCA GCTGAAACGG GCCCTGATGA
AAGTCCAGAT GTTACGGGAA TCACCGTTT GAACAAGACA AGAAGGCCAC
TGGTAGCTAA CGTGTCCGAA ACCAGTTAAG AATGGAAGAA AACGGTGCAT
35 CCACGCACAC ATGGACACAG ACCCACACAT GTTTACAGAA CTGTTGTTA

CTTGTTGCTG ATTCAAGAAA CAGAAGTAGA AGAGAGAGGA TTCTGGTCTT
 CACTGCCATG CCTCAAGAAC ACCTTTGTTT TGCAGTGACA AGATGGAAAA
 TAAATTATAT TAATTTTGA AACCCATTAG GCATGCCTAA TATTTAGGCA
 AGAGAAAATA AACCAAGATA GATCCATTG GACAAAATGG AAGGTTGGAG
 5 ACGTGTATCC CCGTGAAATC TGGTCAGATA ATGAATGATA AGCAGGAAGG
 ATGGCAAGCA CGGGACAGGA GGGGCCACA ATGGAGTGGG AGATCAGCCA
 CGGAGCCTGG AGGGACGCCA CCCAGCAACA CAGAGCTGGC GACTGCAGCT
 GCACCATCAC ACATGCATCA TCAGCCTATT TGTAATATGT CTGCCACAGA
 GAGTCCTTTG GGATTCTAGG AAACCCAAGG ACAAAGAGAA AAAACTAGAG
 10 CCTGTGCTAA AGAAGCCTGC TGGGCCATG TGAGGCTGGG GTCGTAAATA
 TTCCCCGACG ACACTGAAGA ATCAAGAGGG CAGCCCCCAC TTCTCCTACA
 AAATGGAGGG AGCCATCCCT TCCCTGTCCA CCTCACCAAGG GGTGCTATGA
 CATGCAAGTG AGAAGCTGGG CATGAACGCA CTTTATAAAA GCAAAGCTC
 TGTGTAAATC TAACTACAAG GACAATGCCT TGGGAGAGAT TTTGTCGGGA
 15 CAGAGAGGAG TTGCCAGGG AAGAGGTTTAAAGATACGG TTGTCTAGAG
 GTGAGACCAA AGGATCCAGA GACTTGGGG AAGAGGTGA CAGTGGATGA
 CGTGAAGCCA CAGGAGCCCC ACCCCCCATGC AGCTTTTCC CCACCCCCC
 CACCACGCGC TCAATCATGA GTACCTCAAA GGATTGTTGG GCTTGGGGGA
 AAAGAGGTGG ATTCCCTGGC AAGAACCTAA AGTAGCAGGA (SEQ ID NO:11).

20 Another specific embodiment of the present invention
 relates to isolated biologically active fragments or mutants of a
 nucleic acid molecule encoding human uncoupling protein 3,
 disclosed herein as SEQ ID NO:11 (see also Figure 1A-1B). Any such
 polynucleotide includes but is not necessarily limited to nucleotide
 25 substitutions, deletions, additions, amino-terminal truncations and
 carboxy-terminal truncations such that these mutations encode
 mRNA which express a protein or protein fragment of diagnostic,
 therapeutic or prophylactic use.

The purified nucleic acid molecule of the present
 30 invention may include a deoxyribonucleic acid molecule (DNA), such
 as genomic DNA and complementary DNA (cDNA), which may be
 single (coding or noncoding strand) or double stranded, as well as
 synthetic DNA, such as a synthesized, single stranded
 polynucleotide. The isolated nucleic acid molecule of the present
 35 invention may also include a ribonucleic acid molecule (RNA).

The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.

5 The present invention also relates to a substantially purified human uncoupling protein wherein the native form is substantially localized within mitochondria of skeletal muscle.

10 A preferred aspect of the present invention is disclosed in Figure 2A-2D, Figure 3 and SEQ ID NO:12, the amino acid sequence of the exemplified human uncoupling protein, UCP3, which is as follows:

15 MVGLKPSPDVPTMAVKFLGAGTAACFADLVTPLDTAKVRLQIQGENQAVQTARLV
QYRGVLGTLTMVRTEGPCSPYNGLVAGLQRQMSFASIRIGLYDSVKQVYTPKGAD
NSSLTTRILAGCTTGAMAVTCAQPTDVVKVRFQASIHGPSRSDRKYSGTMDAYRT
IAREEGVRGLWKGLPNIMRNAIVNCAEVVTDYLKEKLLDYHLLTDNFPCHFVSA
20 FGAGFCATVVASPVDVVKTRYMNSPPGQYFSPLDCMIKMVAQEGPTAFYKGFTPSF
LRLGSWNVVMFVTYEQLKRALMKVQMLRESPF, as set forth in three-letter
abbreviation in SEQ ID NO:12.

25 The present invention also relates to biologically active fragments and/or mutants of a novel human uncoupling protein, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.

30 The present invention also relates to methods of expressing the vertebrate UCP proteins or protein fragments disclosed herein, assays employing these human and mouse UCPs, cells expressing these UCPs, and compounds identified through the use of these UCPs, including modulators of energy expenditure and body weight regulation, either through direct contact with the mitochondrial uncoupling protein, or a compound which acts in *trans* to modulate ucp expression. Such modulators identified in this process are useful as therapeutic agents for controlling obesity, diabetes and other related diseases.

35 Other uses of the nucleic acid fragment and protein fragments of the present invention include, but are not limited to, identifying trans-

acting factors which regulate UCP3 expression. It will then be possible to identify compounds which affect a protein or protein complex acting in *trans* to up or down regulate vertebrate UCP3 expression such that administration of such a compound or pharmaceutically acceptable salt

5 in a pharmaceutically acceptable formulation will modulate UCP3 expression and in turn the degree of energy expenditure within the patient. It will be known to one of skill in the art that use of such an assay may proceed by construction of a prokaryotic or eukaryotic expression vector wherein a portion of the UCP3 5' non-coding region is

10 fused to an appropriate reporter gene (including but not limited to β -galactosidase) which is utilized to quantitatively measure the effect of a particular compound on UCP3 gene regulation. It will also be possible to identify compounds through screens utilizing recombinant host cells stably or transiently transfected with a UCP3 encoding gene fragment.

15 These compounds will affect, for example, the level of uncoupling of oxidative phosphorylation from ATP synthesis in mitochondria of transfected cells.

Therefore, the present invention also relates to methods of expressing a nucleic acid fragment encoding UCP, including but not limited to the exemplified human and/or mouse *ucp3* or gene fragments disclosed herein, recombinant prokaryotic and eukaryotic expression vectors containing such a nucleic acid fragment, recombinant host cells transfected with these vectors wherein a *ucp* gene or gene fragment is expressed at predetermined levels through appropriate vector construction, and compounds identified through the interaction with either regulatory regions of a *ucp* gene or a compound which interacts with the mature, mitochondrial-localized form of a UCP protein. Such a compound may be useful in treating disorders associated with regulation of body weight and concomitant intake and expenditure of energy (or lack thereof), including but not limited to obesity and diabetes.

To this end, the present invention also relates to a purified or isolated nucleic acid molecule (polynucleotide) which encodes a novel mouse uncoupling protein, as set forth as SEQ ID 35 NO:17, and as follows:

CCAGGAACAG CAGAGACAAC AGTGAATGGT GAGGCCGGC CGTCAGATCC
 TGCTGCTACC TAATGGAGTG GATCCTTAGG GTGGCCCTGC ACTACCCAAC
 CTTGGCTAGA CGCACAGCTT CCTCCCTGAA CTGAAGCAAA AGATTGCCAG
 GCAAGCTCTC TCCTCGGACC TCCATAGGCA GCAAAGGAAC CAGGCCATT
 5 CCCCCGGGACC ATGGTTGGAC TTCAGCCCTC CGAAGTGCCT CCCACAACGG
 TTGTGAAGTT CCTGGGGGCC GGCACTGCGG CCTGTTTGC GGACCTCCTC
 ACTTTTCCCC TGGACACCGC CAAGGTCCGT CTGCAGATCC AAGGGGAGAA
 CCCAGGGGCT CAGAGCGTGC AGTACCGCGG TGTGCTGGGT ACCATCCTGA
 CTATGGTGCG CACAGAGGGT CCCCAGCAGCC CCTACAGCGG ACTGGTCGCT
 10 GGCCTGCACC GCCAGATGAG TTTTGCTCC ATTGAATTG GCCTCTACGA
 CTCTGTCAAG CAGTTCTACA CCCCCAAGGG AGCGGACCAC TCCAGCGTCG
 CCATCAGGAT TCTGGCAGGC TGACGACAG GAGCCATGGC AGTACGACTGC
 GCCCAGCCCA CGGATGTGGT GAAGGTCCGA TTTCAAGCCA TGATACGCCT
 GGGAACTGGA GGAGAGAGGA AATACAGAGG GACTATGGAT GCCTACAGAA
 15 CCATCGCCAG GGAGGAAGGA GTCAGGGGCC TGTGGAAAGG GACTTGGCCC
 AACATCACAA GAAATGCCAT TGTCAACTGT GCTGAGATGG TGACCTACGA
 CATCATCAAG GAGAAGTTGC TGGAGTCTCA CCTGTTTACT GACAACTTCC
 CCTGTCACTT TGTCTCTGCC TTTGGAGCTG GCTTCTGTGC CACAGTGGTG
 GCCTCCCCGG TGGATGTGGT AAAGACCCGA TACATGAACG CTCCCCTAGG
 20 CAGGTACCGC AGCCCTCTGC ACTGTATGCT GAAGATGGT GCTCAGGAGG
 GACCCACGGC CTTCTACAAA GGATTTGTGC CCTCCTTCT GCGTCTGGGA
 GCTTGGAACG TGATGATGTT TGTAAACATAT GAGCAACTGA AGAGGGCCTT
 AATGAAAGTC CAGGTACTGC GGGAAATCTCC GTTTGAACA AGGCAAGCAG
 GCTGCCTGGA ACAGAACAAA GCGTCTCTGC CCTGGGGACA CAGGCCACAA
 25 CGGTCCAGAA CCCTGCACTG CTGCTGACAC GAGAAACTGA ACTAAAAGAG
 GAGAGTTTTA GTCCTCCGTG TTTCGTCCTA AAACACCTCT GTTTGCACT
 GACCTGATGG GAAATAAATT ATATTAATT TTAAACCCCTT TCCGGTTGGA
 TGCCTAACAT TTAGGCAAGA GACAACAAAG AAAACCAGAG TCAACTCCCT
 TGAAATGTAG GAATAAAGGA TGCATAATAA ACAGGAAAGG CACAGGTTTT
 30 GAGAAGATCA GCCCACAGTG TTGTCCTTGA ATCAAACAAA ATGGTCGGAG
 GAACCCCTTCG GGTTCAGCAC AAAGAGGTGA CTACAGCCTT TTGGTCACCA
 GATGACTCCG CCCCTTGTA ATGAGTCTGC CAAGTAGACT CTATCAAGAT
 TCTGGGGAAA GGAGAAAGAA CACATTGACC TGCCCGGGCG GCCGCTCGAG
 CCCTATGA, disclosed as SEQ ID NO:17.

The present invention also relates to mouse forms of isolated biologically active fragments or mutants of a nucleic acid molecule encoding human uncoupling protein 3, disclosed herein as SEQ ID NO:17 (see also Figure 6A-6B). Any such polynucleotide

5 includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment of diagnostic, therapeutic or prophylactic use.

10 The purified mouse nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single 15 stranded polynucleotide. The isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).

20 The present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified mouse nucleic acid molecules disclosed throughout this specification.

The present invention also relates to a substantially purified mouse uncoupling protein wherein the native form is substantially localized within mitochondria of skeletal muscle.

25 A preferred aspect of the present invention is disclosed in Figure 7 and SEQ ID NO:18, the amino acid sequence of the

exemplified mouse uncoupling protein, UCP3, which is as follows:

MVGLQPSEVP PTTVVKFLGA GTAACFADLL TFPLDTAKVR LQIQGENPGA
QSVQYRGVLG TILTMVRTEG PRSPYSGLVA GLHRQMSFAS IRIGLYDSVK

30 QFYTPKGADH SSVAIRILAG CTTGAMAVTC AQPTDVVKVR FQAMIRLGTG
GERKYRGTMD AYRTIAREEG VRGLWKGTWP NITRNAIVNC AEMVTYDIIK

EKLLESHLFT DNFPCHFVSA FGAGFCATVV ASPVDDVKTR YMNAPLGRYR
SPLHCMILKMV AQEGPTAFYK GFVPSFLRLG AWNVMMFVTY EQLKRALMKV

QVLRESPF*, as set forth in three-letter abbreviation in SEQ ID NO:18.

The present invention also relates to biologically active fragments and/or mutants of a novel mouse uncoupling protein, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-

5 terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use.

It is known that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA 10 sequences which contain alternative codons which code for the eventual translation of the identical amino acid. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the 15 translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.

20 It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally-occurring peptide. Methods of altering the DNA sequences include, but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in 25 the affinity of an enzyme for a substrate or a receptor for a ligand.

As used herein, "purified" and "isolated" are utilized interchangibly to stand for the proposition that the nucleic acid, protein, or respective fragment thereof in question has been substantially removed from its *in vivo* environment so that it may be 30 manipulated by the skilled artisan, such as but not limited to nucleotide sequencing, restriction digestion, site-directed mutagenesis, and subcloning into expression vectors for a nucleic acid fragment as well as obtaining the protein or protein fragment in pure quantities so as to afford the opportunity to generate polyclonal antibodies, monoclononal 35 antibodies, amino acid sequencing, and peptide digestion. Therefore,

the nucleic acids claimed herein may be present in whole cells or in cell lysates or in a partially purified or substantially purified form. A nucleic acid is considered substantially purified when it is purified away from environmental contaminants. Thus, a nucleic acid sequence

5 isolated from cells is considered to be substantially purified when purified from cellular components by standard methods while a chemically synthesized nucleic acid sequence is considered to be substantially purified when purified from its chemical precursors.

As used herein, "UCP3" may refer to any vertebrate form of UCP3, 10 including but not limited to mouse or human UCP3.

As used herein, "BAT" means brown adipose tissue.

As used herein, "EST" means expressed sequence tag.

As used herein, a "biologically active equivalent" or "functional derivative" of a wild type UCP3 possesses a biological 15 activity that is substantially similar to the biological activity of the wild type UCP3. The term "functional derivative" is intended to include the "fragments," "mutants," "variants," "degenerate variants," "analogs" and "homologues" or to "chemical derivatives" of the wild type UCP3 protein. The term "fragment" is meant to refer to 20 any polypeptide subset of wild type UCP3. The term "mutant" is meant to refer to a molecule that may be substantially similar to the wild type form but possesses distinguishing biological characteristics. Such altered characteristics include but are in no way limited to altered substrate binding, altered substrate affinity 25 and altered sensitivity to chemical compounds affecting biological activity of the UCP3 or UCP3 functional derivative. The term "variant" is meant to refer to a molecule substantially similar in structure and function to either the entire wild type protein or to a fragment thereof. A molecule is "substantially similar" to a wild type 30 UCP3-like protein if both molecules have substantially similar structures or if both molecules possess similar biological activity. Therefore, if the two molecules possess substantially similar activity, they are considered to be variants even if the structure of one of the 35 molecules is not found in the other or even if the two amino acid sequences are not identical.

The term "analog" refers to a molecule substantially similar in function to either the entire wild type UCP3-like protein or to a fragment thereof.

Any of a variety of procedures may be used to clone UCP3. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, *Proc. Natl. Acad. Sci.* 85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of UCP3 cDNA. These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the UCP3 cDNA following the construction of an UCP3-containing cDNA library in an appropriate expression vector system; (3) screening a UCP3-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the UCP3 protein; (4) screening a UCP3-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the UCP3 protein. This partial cDNA is obtained by the specific PCR amplification of UCP3 DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other UCP3 kinases which are related to the UCP3 protein; (5) screening an UCP3-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the UCP3 protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of UCP3 cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using SEQ ID NOS 1 or 2 as a template so that either the full length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same

known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full length version of the nucleotide sequence encoding UCP3.

5 It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cells types or species types, may be useful for isolating a UCP3-encoding DNA or a UCP3 homologue. Other types of libraries include, but are not limited to, cDNA libraries derived from other
10 cells or cell lines other than human cells or tissue such as murine cells, rodent cells or any other such vertebrate host which may contain a UCP3-encoding DNA. Additionally a UCP3 gene may be isolated by oligonucleotide- or polynucleotide- based hybridization screening of a vertebrate genomic library, including
15 but not limited to a human genomic library, a murine genomic library and a rodent genomic library, as well as concomitant human genomic DNA libraries.

It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have UCP3 activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate a UCP3 cDNA may be done by first measuring cell associated UCP3 activity using any known assay for UCP3 activity.

Preparation of cDNA libraries can be performed by
25 standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook, et al., 1989, *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Complementary DNA libraries may also be obtained from
30 numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene.

It is also readily apparent to those skilled in the art that DNA encoding UCP3 may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries
35 can be performed by standard techniques well known in the art.

Well known genomic DNA library construction techniques can be found in Sambrook, et al., *supra*.

In order to clone the UCP3 gene by one of the preferred methods, the amino acid sequence or DNA sequence of

5 UCP3 or a homologous protein may be necessary. To accomplish this, the UCP3 or a homologous protein may be purified and partial amino acid sequence determined by automated sequenators. It is not necessary to determine the entire amino acid sequence, but the linear sequence of two regions of 6 to 8

10 amino acids can be determined for the PCR amplification of a partial UCP3 DNA fragment. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized. Because the genetic code is degenerate, more than one codon may be used to encode a

15 particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the UCP3 sequence but others in the set will be capable of hybridizing to UCP3 DNA even in the presence of DNA oligonucleotides with mismatches.

20 The mismatched DNA oligonucleotides may still sufficiently hybridize to the UCP3 DNA to permit identification and isolation of UCP3 encoding DNA. Alternatively, the nucleotide sequence of a region of an expressed sequence may be identified by searching one or more available genomic databases. Gene-specific primers

25 may be used to perform PCR amplification of a cDNA of interest from either a cDNA library or a population of cDNAs. As noted above, the appropriate nucleotide sequence for use in a PCR-based method may be obtained from SEQ ID NOS: 1 or 2, either for the purpose of isolating overlapping 5' and 3' RACE products for

30 generation of a full-length sequence coding for UCP3, or to isolate a portion of the nucleotide sequence coding for UCP3 for use as a probe to screen one or more cDNA- or genomic-based libraries to isolate a full-length sequence encoding UCP3 or UCP3-like proteins.

In an exemplified method, the human UCP3 full length cDNA of the present invention was generated by a novel method of cDNA screening. Briefly, the extension of partial cDNA sequences have historically been achieved with one or both of the two commonly used 5 methods: filter screening of cDNA libraries by hybridization with labeled probes, and 5'- and 3'-RACE with total cellular mRNA by PCR. The first method is effective but laborious and slow while the latter method is fast but limited in efficiency. This RACE protocol is hindered by limited 10 length of extension due to the use of the entire cellular mRNA population in a single reaction. Since smaller fragments are amplified much more efficiently than larger fragments by PCR in the same reaction, PCR products obtained using the second method are often quite 15 small. This portion of the present invention marks an improvement upon known methods of cDNA library screening by initially constructing and subdividing cDNA libraries followed by isolating 5'- and 3'- flanking fragments by PCR. Since each pool is unlikely to contain more than one clone for a given gene which is low to moderately 20 expressed, competition between large and small PCR products in one pool does not exist, making it possible to isolate fragments of various sizes. One definite advantage of the method disclosed in this specification is the efficiency, throughput, and its potential to isolate 25 alternatively spliced cDNA forms.

Therefore, this portion of the invention relates to a process for rapid extension of a partial cDNA sequence based on subdividing a 25 primary cDNA library and DNA amplification by polymerase chain reaction (PCR). A cDNA library is constructed with cDNA primed by random, oligo-dT or a combination of both random and oligo-dT primers and then subdivided into pools at approximately 10,000 -20,000 clones per pool. Each pool is amplified separately and therefore represents an 30 independent portion of the cDNA molecules from the original mRNA source. Samples from all the pools are collected and transferred into 96-well plates. To extend a partial cDNA sequence, such as SEQ ID NO:1 or 2, positive pools containing the partial cDNA sequence are first 35 identified by PCR with a pair of primers complementary to the cDNA sequence. Each positive pool in the library contains an independent

clone of the cDNA sequence; within each clone are embedded the partial cDNA sequence and its flanking fragments. The flanking fragments are isolated by PCR with primers complementary to the known vector and cDNA sequences and then sequenced directly. The DNA sequences from these fragments plus the original partial cDNA sequence are assembled into a continuous fragment, resulting in the extension of the partial cDNA sequence and the eventual determination of its full-length gene sequence by repeating the process, if necessary, until a complete open reading frame is obtained.

The fundamental principle of this process is to subdivide a complex library into pools of about 10,000 to about 20,000 clones. A library of two million primary clones, a number large enough to cover most mRNA transcripts expressed in the tissue, can be subdivided into 188 pools and stored in two 96-well plates. Since the number of transcripts for most genes is fewer than one copy per ~10,000 transcripts in total cellular mRNA, each pool is unlikely to contain more than one clone for a given cDNA sequence. Such reduced complexity makes it possible to use PCR to isolate flanking fragments of partial cDNA sequences larger than those obtained by known methods.

The foregoing process is exemplified for isolation and characterization of a full-length cDNA encoding human UCP3. Briefly, a random and oligo dT primed fetal brain cDNA library consisting of approximately 4 million primary clones was constructed in the plasmid vector pBluescript (Stratagene, LaJolla, CA). The primary clones were subdivided into 188 pools with each pool containing ~20,000 clones. Each pool was amplified separately and the resulting plasmid pools were collected and transferred into two 96-well plates. Primer pairs from the 5' and 3' portion of SEQ ID NO:1 (EST-AA192136), 5' and 3' oligonucleotides from SEQ ID NO:4 (EST-AA192553) as well as oligonucleotide primers both 5' and 3' of the polylinker sequence of the vector (in this case, pBluescript SK⁻) were used to scan this human fetal brain cDNA library distributed in a 96-well plate separately. Initial positive pools were identified with the 5' and 3' primers from AA192136 (SEQ ID NOS: 5 and 6) and the pBluescript primers (SEQ ID NOS:9 and 10). The positive pools were scanned again by PCR with both pBluescript

primers as well as the 5' and 3' primers associated with the 3' EST, AA192553 (primers 3U3F and 3U3R). This step showed that scanning with 838F (pBSK⁻, SEQ ID NO: 9) and 3U3F (hybridizing to the 3' EST AA192553; SEQ ID NO:8), generated a 2.4 Kb cDNA fragment. This 5 cDNA fragment was subcloned into the vector pTA2.1 (Invitrogen, San Diego, CA, USA) by TA cloning. Four positive clones, the original PCR fragment, as well the I.M.A.G.E. clone #628529 (SEQ ID NOS:1 and 2) were sequenced by primer walking. The sequences were then 10 assembled into a contig of 2340 base pairs which is as set forth in SEQ ID NO:11 and Figure 1A and Figure 1B. This sequence contains an open reading frame that encodes a polypeptide of 312 amino acids as set forth in SEQ ID NO:12 and Figures 2A-2D and Figure 3.

The cDNA as set forth in SEQ ID NO:11 was identified as a full-length cDNA fragment from a single positive pool. Figure 5 shows the 15 vector and EST (gene) specific primers used to isolate the human UCP3 gene. In this instance, the entire coding region and 3' untranslated region was retrieved by the 838F and 3U3F primer combination. However, the skilled artisan, aided with this specification, will 20 understand the more far reaching cDNA cloning process disclosed herein: multiple primer combinations from an EST or other partial cDNA sequence, in combination with flanking vector primer oligonucleotides may be used to "walk" in both directions away from the internal gene specific sequence and respective primers such that a 25 contig representing a full length cDNA may be constructed. This procedure relies on the ability to screen multiple pools which comprise a representative portion of the total cDNA library. This procedure is not dependent upon using a cDNA library with directionally cloned inserts. Instead, both 5' and 3' vector and gene specific primers are added and a 30 contig map is constructed from additional screening of positive pools using both vector primers and gene specific primers. Of course, these gene specific primers are initially constructed from a known nucleic acid fragment such as an expressed sequence tag. However, as the walk continues, gene specific primers are utilized from the 5' and 3' boundaries of the newly identified regions of the cDNA. As the walk

continues, there is still no requirement that the vector orientation of a yet unidentified fragment be known. Instead, all combinations are tested on a positive pool and the actual vector orientation is determined by the ability of certain vector/gene specific primers to generate the 5 predicted PCR fragment. A full-length cDNA may then be easily constructed by known subcloning procedures.

A variety of mammalian expression vectors may be used to express recombinant UCP3 in mammalian cells. Expression vectors are defined herein as DNA sequences that are required for the 10 transcription of cloned DNA and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells. 15 An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA 20 and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses.

Commercially available mammalian expression vectors 25 which may be suitable for recombinant UCP3 expression, include but are not limited to, pcDNA3.1 (Invitrogen), pBlueBacHis2 (Invitrogen), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Bioloabs), pcDNAI, pcDNAIamp (Invitrogen), pcDNA3 (Invitrogen), pMC1neo (Stratagene), pXT1 (Stratagene), pSG5 (Stratagene), EBO- 30 pSV2-neo (ATCC 37593) pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and IZD35 (ATCC 37565).

A variety of bacterial expression vectors may be used to 35 express recombinant UCP3 in bacterial cells. Commercially available

bacterial expression vectors which may be suitable for recombinant UCP3 expression include, but are not limited to pCR2.1 (Invitrogen), pET11a (Novagen), lambda gt11 (Invitrogen), pcDNAII (Invitrogen), pKK223-3 (Pharmacia).

5 A variety of fungal cell expression vectors may be used to express recombinant UCP3 in fungal cells. Commercially available fungal cell expression vectors which may be suitable for recombinant UCP3 expression include but are not limited to pYES2 (Invitrogen), *Pichia* expression vector (Invitrogen).

10 A variety of insect cell expression vectors may be used to express recombinant receptor in insect cells. Commercially available insect cell expression vectors which may be suitable for recombinant expression of UCP3 include but are not limited to pBlueBacIII and pBlueBacHis2 (Invitrogen).

15 An expression vector containing DNA encoding a UCP3-like protein may be used for expression of UCP3 in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), Saos-2 (ATCC HTB-85), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171).

20 The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. The expression vector-containing cells are individually analyzed to determine whether they produce UCP3 protein. Identification of UCP3 expressing cells may be done by several means, including but not

25

30

35

limited to immunological reactivity with anti-UCP3 antibodies, and the presence of host cell-associated UCP3 activity.

The cloned UCP3 cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning 5 into an expression vector (such as pcDNA3.1, pCR2.1, pBlueBacHis2 and pLITMUS28) containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant UCP3. Techniques for such manipulations can be found described in Sambrook, et al., *supra*, 10 are discussed at length in the Example section and are well known and easily available to the artisan of ordinary skill in the art.

Expression of UCP3 DNA may also be performed using *in* vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to 15 wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.

To determine the UCP3 cDNA sequence(s) that yields 20 optimal levels of UCP3 protein, UCP3 cDNA molecules including but not limited to the following can be constructed: the full-length open reading frame of the UCP3 cDNA and various constructs containing portions of the cDNA encoding only specific domains of the protein or rearranged domains of the protein. All constructs can be designed to contain none, 25 all or portions of the 5' and/or 3' untranslated region of UCP3. UCP3 activity and levels of protein expression can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells. Following determination of the UCP3 cDNA cassette yielding optimal expression in transient assays, this UCP3 30 cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells.

Levels of UCP3 protein in host cells is quantified by a variety 35 of techniques including, but not limited to, immunoaffinity and/or

ligand affinity techniques. UCP3-specific affinity beads or UCP3-specific antibodies are used to isolate ³⁵S-methionine labeled or unlabelled UCP3 protein. Labeled UCP3 protein is analyzed by SDS-PAGE. Unlabelled UCP3 protein is detected by Western blotting, ELISA or RIA assays
5 employing UCP3 specific antibodies.

Following expression of UCP3 in a host cell, UCP3 protein may be recovered to provide UCP3 in active form. Several UCP3 purification procedures are available and suitable for use. Recombinant UCP3 may be purified from cell lysates and extracts, or from
10 conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography.

In addition, recombinant UCP3 can be separated from
15 other cellular proteins by use of an immuno-affinity column made with monoclonal or polyclonal antibodies specific for full length UCP3, or polypeptide fragments of UCP3. Additionally, polyclonal or monoclonal antibodies may be raised against a synthetic peptide (usually from about 9 to about 25 amino acids in length) from a portion of the protein as
20 disclosed in SEQ ID NO:12. Monospecific antibodies to UCP3 are purified from mammalian antisera containing antibodies reactive against UCP3 or are prepared as monoclonal antibodies reactive with UCP3 using the technique of Kohler and Milstein (1975, *Nature* 256: 495-497). Monospecific antibody as used herein is defined as a single
25 antibody species or multiple antibody species with homogenous binding characteristics for UCP3. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the UCP3, as described above. UCP3 specific antibodies are raised by immunizing animals such as mice,
30 rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of UCP3 or UCP3 synthetic peptide either with or without an immune adjuvant.

Preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 mg and about
35 1000 mg of UCP3 associated with an acceptable immune adjuvant. Such

acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA. The initial immunization consists of the UCP3 protein or UCP3 synthetic peptide in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are 5 generally given an equal amount of UCP3 in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single 10 immunization, the animals are bled, the serum collected, and aliquots 15 are stored at about -20°C.

Monoclonal antibodies (mAb) reactive with UCP3 are prepared by immunizing inbred mice, preferably Balb/c, with UCP3. The mice are immunized by the IP or SC route with about 1 mg to about 100 mg, preferably about 10 mg, of UCP3 in about 0.5 ml buffer or saline 20 incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 mg of UCP3 in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes, from 25 antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable 30 hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from 35 about 30% to about 50%. Fused hybridoma cells are selected by growth in

hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using UCP3 as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, 1973, *Soft Agar Techniques*, in *Tissue Culture Methods and Applications*, Kruse and Paterson, Eds., Academic Press.

Monoclonal antibodies are produced *in vivo* by injection of pristine primed Balb/c mice, approximately 0.5 ml per mouse, with about 2×10^6 to about 6×10^6 hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.

In vitro production of anti-UCP3 mAb is carried out by growing the hybridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of UCP3 in body fluids or tissue and cell extracts.

It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be utilized to produce antibodies specific for UCP3 polypeptide fragments, or full-length UCP3 polypeptide.

UCP3 antibody affinity columns are made by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are

then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine HC1 (pH 8). The column is washed with water followed by 0.23 M glycine HC1 (pH 2.6) to remove any non-conjugated antibody or

5 extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing UCP3 or UCP3 fragments are slowly passed through the column. The column is then washed with phosphate buffered saline until the optical density (A_{280}) falls to background, then the protein is

10 eluted with 0.23 M glycine-HCl (pH 2.6). The purified UCP3 protein is then dialyzed against phosphate buffered saline.

The novel UCP3 of the present invention is suitable for use in an assay procedure for the identification of compounds which modulate UCP3 activity. Modulating UCP3 activity, as described herein

15 includes the inhibition or activation of the protein and also includes directly or indirectly affecting the cell cycle regulatory properties associated with UCP3 activity. Compounds which modulate UCP3 activity include agonists, antagonists, inhibitors, activators, and compounds which directly or indirectly affect regulation of the UCP3

20 activity and/or the UCP3 uncoupling activity.

The UCP3 of the present invention may be obtained from both native and recombinant sources for use in an assay procedure to identify UCP3 modulators. In general, an assay procedure to identify UCP3 modulators will contain the UCP3-protein of the present

25 invention, and a test compound or sample which contains a putative UCP3 modulator. The test compounds or samples may be tested directly on, for example, purified UCP3 protein whether native or recombinant, subcellular fractions of UCP3-producing cells whether native or recombinant, and/or whole cells expressing the UCP3 whether native or

30 recombinant. The test compound or sample may be added to the UCP3 in the presence or absence of a known UCP3 modulator. The modulating activity of the test compound or sample may be determined by, for example, analyzing the ability of the test compound or sample to bind to UCP3 protein, activate the protein, inhibit UCP3 activity, inhibit

or enhance the binding of other compounds to the UCP3 protein, modifying receptor regulation, or modifying an intracellular activity.

Therefore, the present invention also relates to subcellular membrane fractions of the recombinant host cells (both 5 prokaryotic and eukaryotic as well as both stably and transiently transformed cells) comprising the nucleic acids of the present invention. These subcellular membrane fractions will comprise UCP3 at levels substantially above wild type levels and hence will be useful in various assays described throughout this specification.

10 The identification of modulators of UCP3 activity will be useful in treating disease states involving, as an example but not a limitation, obesity and diabetes, by manipulating the interrelated process of balancing food intake, energy expenditure and glucose metabolism within the patient. Therefore, modulators to treat 15 hyperactive conditions of energy expenditure which originate in the mitochondria of skeletal muscle will also be within the purview of the present invention.

The present invention is also directed to methods for screening for compounds which modulate the expression of DNA or 20 RNA encoding a UCP3 protein of the present invention or which modulates the function of a such a UCP3 protein. Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules. Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding the 25 UCP3 protein, or the function of a UCP3 protein. Compounds that modulate the expression of DNA or RNA encoding the UCP3 protein or the biological function thereof may be detected by a variety of assays. The assay may be a simple "yes/no" assay to determine whether there is a change in expression or function. The assay may be made 30 quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample. Kits containing modified UCP3, antibodies to UCP3, or modified UCP3 protein may be prepared by known methods for such uses.

The DNA molecules, RNA molecules, recombinant protein 35 and antibodies of the present invention may be used to screen and

measure levels of UCP3 DNA, RNA or protein. The recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of UCP3. Such a kit would comprise a compartmentalized carrier

5 suitable to hold in close confinement at least one container. The carrier would further comprise reagents such as recombinant UCP3 protein or anti-UCP3 antibodies suitable for detecting UCP3. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.

10 Pharmaceutically useful compositions comprising modulators of UCP3 may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically

15 acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein, DNA, RNA, or modified UCP3.

20 Therapeutic or diagnostic compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders. The effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.

25 The pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.

30 The term "chemical derivative" describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.

Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages. Alternatively, co-

administration or sequential administration of other agents may be desirable.

The present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical

5 formulations for use in the novel methods of treatment of the present invention. The compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compounds can be administered
10 in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or
15 without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.

20 Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will,
25 of course, be continuous rather than intermittent throughout the dosage regimen.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents can be administered concurrently, or they each can be
30 administered at separately staggered times.

The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the
35 renal and hepatic function of the patient; and the particular compound

thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range 5 that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.

By computer analysis of a genomic database, molecular 10 cloning and DNA sequencing a novel member of the human UCP3 gene family has been identified. This new cDNA fragment encodes a novel human uncoupling protein which may be useful as a gene therapy vehicle or a drug target in such diseases as obesity and diabetes.

15 Northern hybridization experiments with RNA from various cell and tissues indicates that UCP3 is expressed in various human tissue, including skeletal muscle, brain, and heart, with predominant expression in skeletal muscle.

The following examples are provided as illustrative of the present invention without, however, limiting the same thereto.

20

EXAMPLE 1:
Identification of Partial DNA Fragments Encoding Human UCP3

25 The nucleotide sequence for human UCP1 (Cassard et al., 1990, *J. Cell. Biochem.* 43: 255-264) is deposited in Genbank and is assigned accession number U28480. The nucleotide sequence for human UCP2 (Fleury et al., 1997, *Nature Genetics* 15: 269-272) is deposited in Genbank and is assigned accession number U76367. The nucleotide 30 sequences of UCP1 and UCP2 were used to search the Genbank EST sequences by Blastn (see Altschull et al., 1990, *J. Mol. Biol.* 215: 403-410). The Blastn search identified an expressed sequence tag (EST) detected among the Merck-Washington University EST's with accession number AA192136, which is:

GGTGACCTACGACATCCTCAAGGAGAAGCTGCTGGACTACCACCTGCTCACTGACA
 AACT
 TCCCCTGCCACTTGTCTGCCTTGGAGCCGGCTCTGTGCCACAGTGGTGGCATCC
 CCGGTGGACGTGGTGAAGACCCGGTATATGAACTCACCTCCAGGCCAGTACTTCAGCCC
 CCTCGACTGTATGATAAAAGATGGTGGCCCAGGAGGCCACCAGCCTCTACAAGGGATT

5 TACACCCTCCTTTGCCTTGGGATCCTGGAACGTGGTATGTTCGTAACCTATGAGC
 AGCTGAAACGGGCCCTGATGAAAGTCCAGATGTTACGGGAATCACCCTTTGAACAAGA
 CAAGAAGGCCACTGGTAGCTAACGTGTCCGAAACCAGTTAAGAATGGAAG
 (SEQ ID NO:1).

An "N" residue is added at base number 249 in order to preserve the open
 10 reading frame of this EST. This corrected version of AA192136 is as
 follows:

GGTGACCTACGACATCCTCAAGGAGAAGCTGCTGGACTACCACCTGCTCACTGACA
 AACT
 TCCCCTGCCACTTGTCTGCCTTGGAGCCGGCTCTGTGCCACAGTGGTGGCATCC
 CCGGTGGACGTGGTGAAGACCCGGTATATGAACTCACCTCCAGGCCAGTACTTCAGCCC

15 CCTCGACTGTATGATAAAAGATGGTGGCCCAGGAGGCCACCAGCCTCTACAAGGGATT
 TACACCCTCCTNTTGCGTTGGGATCCTGGAACGTGGTATGTTCGTAACCTATGAG
 CAGCTGAAACGGGCCCTGATGAAAGTCCAGATGTTACGGGAATCACCCTTTGAACAAG
 ACAAGAAGGCCACTGGTAGCTAACGTGTCCGAAACCAGTTAAGAATGGAAG(SEQ ID
 NO:2).

20 SEQ ID NO:1 is a component of Stratagene® muscle cDNA library
 937209 and is identified as cDNA Image Clone No. 628529. This
 Stratagene muscle cDNA library was generated by standard methods
 and cDNAs are cloned unidirectionally into EcoRI/XhoI digested
 pBS(SK-) plasmid. The mRNA for this library was isolated from the
 25 skeletal muscle of an adult human patient suffering from malignant
 hyperthermia. This cDNA clone is publically available by Genbank
 Accession No. AA192136, Image Clone ID No. 628529, and Washington
 University Clone ID No. zq02d09.r1. This construct is available from
 Research Genetics, Inc., 2130 Memorial Parkway SW, Hunstville, AL
 30 35801 (<http://www.resgen.com>).

SEQ ID NO:1 was used as a query to search Genbank with Blastn.
 A second EST, with accession number Z28895 (and assigned Genbank
 number HSBB6C051) was identified and is disclosed throughout this
 specification as SEQ ID NO:3, which is:

199591
CGAGCAGCTGAAACGGGCCCTGATGAAAGTCCAGATGTTACGGGNATCACC GTT TGAA
CAAGACAAGAAGGCCACTGGTAGCTAACGTNTCCGAAACCAGTTAAGANTGGAAGAAAA
CGGTCCATCCACGNACACATGGACACAGACCCACACATNTT (SEQ ID NO:3).

The EST disclosed as SEQ ID NO:2 shows an open reading frame
5 encoding a novel protein fragment showing homology to human UCP1
and human UCP2. SEQ ID NO:2 represents the 5' portion of the cDNA
Image Clone No. 628529. The 3' sequence read of cDNA Image Clone
No. 628529 has the accession number aa192553, which is as follows:

TTTTTTTTGTTCTTACTCCCACACCTAACGGT GGAANTCTTTATTGAGTCATAATAAT
10 TTCCCGAGAATTCCGAGTCCTGCTACTTAGGTTCTGCCAGGAATCCACCTCTTTC
CCCCAAGCCAAACAATCCTTGAGGTACTCATGATTGAGCGCGTGGTGGGGGGGGTGG
GGAAGAGGCTGCATGGGGTGGGCTCTGTGGCTCACGTACCCACTGTCACCTCTG
GTCCCCAAGTCTGGATCCTTGCTCACCTCTAGACAACCGGCGGGGTTCAAACCT
TCTTCCCTGGCAACTCCTCTGTCCCGACAAAATCTCTCCAAGGCATTGTCCTTGTA
15 GTTAGATTACACAGAGCTTGCTTTATAAAAGTGC GTTCATGCCAGCTCTCACTT
GCATGTCATAGCACCCCTGGTGAGGTGGACAGGGAAAGGGATGGCTCCCTCCATTGTA
GGAAAGTNGGGG (SEQ ID NO:4).

20

EXAMPLE 2:

Isolation and Characterization of DNA Fragments Encoding Full-Length Human UCP3

25 The exemplified full length cDNA of the present invention was
generated by a novel method of cDNA screening as described in the
Detailed Description of the Invention.

The foregoing process is exemplified for isolation and
characterization of a full-length cDNA encoding human UCP3. Briefly,
a random oligo dT primed fetal brain cDNA library consisting of
30 approximately 4.0 million primary clones was constructed in the
plasmid vector pBluescript (Stratagene, LaJolla, CA). The primary
clones were subdivided into 188 pools with each pool containing
approximately 20,000 clones. Each pool was amplified separately and
the resulting plasmid pools were collected and transferred into two
35 96-well plates.

Primer pairs 5'-AAGCTGCTGGACTACCACCTGCTC-3' (F29; SEQ ID NO:5), 5'-TACTGGCCTGGAGGTGAGTTCA-3' (R147; SEQ ID NO:6) as designed from AA192136; 5'-CCAAGCCAACAAATCCTTGA-3' (3U3F; SEQ ID NO:7) and 5 5'-CCAAAGGATCCAGAGACTTGG-3' (3U3R; SEQ ID NO:8) as designed from AA192553, and pBluescript SK vector primers 838F (5'-TTGTGTGGAATTGTGAGCGGATAAC-3'; SEQ ID NO:9) and 578R (5'-CCAGGGTTTCCCAGTCACGAC-3'; SEQ ID NO:10) were used to scan by PCR a human fetal brain cDNA library distributed in a 96-well 10 plate separately. Both the F29/R147-838F/578R scan and the 3U3F/3U3R-838F/578R scans scored positive in pools D10, E10 and F2. Gene specific primer 3U3F (SEQ ID NO:8, the 5' oligonucleotide from the 3' EST (AA192553, SEQ ID NO:4) and pBluescript SK vector primer 838F SEQ ID NO:9) amplified a fragment of about 2.4 kb from both pool E10 and pool 15 F2. The fragments from E10 and F2 were gel purified, mixed, subcloned into the vector pTA2.1 (Invitrogen, San Diego, CA, USA) by TA cloning. Four positive clones, the original PCR fragment, as well the I.M.A.G.E. clone #628529 (SEQ ID NOS:1 and 2) were sequenced by primer walking. The sequences were then assembled into a contig of 2340 base pairs 20 which is as set forth in SEQ ID NO:11 and shown in Figure 1A-1B. This sequence contains an open reading frame that encodes a polypeptide of 312 amino acids as set forth in SEQ ID NO:12 and shown in Figure 2A-2D and Figure 3.

25

EXAMPLE 3:

Construction of a Yeast Expression Vector and Transformed Yeast Cell Line Expressing Human UPC3

A pair of primers, UCP3.-9F.RI20mer
30 (5'CATAGAATTCCAGGACTATGGTTGGAC3', SEQ ID NO:13), and UCP3.1308R.XhoI20mer

(5'CATTCTCGAGCTACCAGTGGCCTTCTTG3', SEQ ID NO:14) were used to generate a PCR product of human UCP3 tagged with EcoRI and XhoI sites at the 5' and 3' ends, respectively, using pCR2.1-UCP3.1 as the template. The PCR product was digested with EcoRI and XhoI and purified from an agarose gel. This fragment was ligated into a yeast expression vector pYES2 (Invitrogen, San Diego, CA) that was also digested with EcoRI and XhoI such that UCP3 is under the control of *S. cerevisiae* GAL1 promoter. Multiple recombinants isolated after transformation into *E. coli* were picked and sequenced using three UCP3 internal primers in combination with two pYES2 vector primers (5'CCCGGATCGGACTACTAGCA, (SEQ ID NO:15); 5'GGGGGGAGGGCGTGAATGTAA; [SEQ ID NO:16]). Mutation-free clones of pYES2-UCP3 were then transformed into two *Saccharomyces cerevisiae* strains INVSc1 (*MATA*, *his3D1*, *leu2*, *trp1-289*, *ura3-52*) and YPH499(*MATA*, *ura3-52*, *lys2-801*, *ade2-101*,*trp1-D63*, *his3-D200*, *leu2-D1*) using lithium acetate method and selected on Sc-ura media. The expression of UCP3 was achieved by induction in Sc-ura media with 2% galactose and 3% glycerol.

The diploid *Saccharomyces cerevisiae* strain W303 (*MATA/a*, *can1-100*, *ade2-10*, *his3-11,-15*, *leu2-2,-112*, *trp1-D1*, *ura3-1*) was also used for the expression of UCP3. Human UCP3 was expressed under the control of GAL1 promoter in pYES2 (Invitrogen, San Diego, CA). Constructs were made directly in yeast using a gap repair strategy. The entire open reading frame of human UCP3 was amplified using a pair of primers that incorporated a yeast translation start site (ATAATG). Taq Additive (Stratagene, La Jolla, CA) was included in PCR reaction to enhance amplification fidelity. The PCR product was fused to GAL1 at the 5' end and to CYC1 terminator at the 3' end by co-transforming the PCR product and pYES2 followed by selection on Sc-Ura medium. More than 50% of the transformants contained the expected GAL1-UCP3 plasmids. Consistent results were obtained from multiple independent clones for growth and flow cytometry analysis. For the growth assay, the W303 strain containing the vector alone or UCP3 expression plasmid was streaked onto Sc-Ura media with 3%

glycerol and 2% galactose and incubated at 30°C for 48 hours. To measure mitochondria membrane potential, cells were grown in Sc-Ura media supplemented with raffinose. Galactose was added to induce the expression of UCP3 for five hours. Fluorescent probe DiOC6 (3,3'-dihexyloxacarbocyanine iodine) was added after cell concentration was adjusted to two millions per ml. Data were collected and analyzed as described (Bouillaud et al., 1994. *EMBO J.* 13: 1990-1997). A total 10,000 objects were taken for the histograms. For the display of fluorescence intensity, a three-order logarithmic scale was used.

10 The biochemical activity of UCP1 and UCP2 have previously been studied by measuring the defects of aerobic growth in yeast expressing UCPs. To test that UCP3 encodes an uncoupling protein for mitochondria, UCP3 was expressed under the control of a tightly inducible promoter *GAL1* in the yeast system as previously described for UCP1 and UCP2 (Fleury et al., 1997, *Nature Genetics* 15: 269-272; Gimeno et al., 1997, *Diabetes* 46, 900-906). Induction with galactose resulted in a significant decrease in the growth rate of strains containing UCP3 relative to cells with vector alone. To confirm more directly that UCP3 reduced the mitochondria membrane potential, the 15 fluorescent intensity of cells labeled with the potential sensitive dye DiOC6 was measured using flow cytometry analysis. Induction of UCP3 expression by galactose significantly reduced the membrane potential of mitochondria compared with strains containing vector alone (Figure 8A and 8C). In addition, no membrane potential shift was observed when 20 UCP3 expression was not induced (Figure 8B). Two membrane potential peaks were observed after UCP3 induction (Figure 8C). Similar results were observed for UCP2 (Fleury et al., 1997, *Nature Genetics* 15: 269-272). The most likely explanation for this observation is that one peak represents cells with reduced membrane potential due to expression of 25 UCP3 while the other peak represents cells with normal membrane potential due to the loss of UCP3 expression. When UCP2 was cloned into the same vector as UCP3 and transformed into the same yeast strain, UCP3 reduced membrane potential to a greater extent compared with UCP2. The data indicate that UCP3 encodes an uncoupling protein 30 that is able to decrease the membrane potential of mitochondria.

35

EXAMPLE 4:

Tissue Distribution Of UCP3 Expression

5 Human multiple tissue Northern Blot #7760-1, Human
Brain Northern Blot II #7755-1, Human Brain Northern Blot III
#7750-1, and Human multiple tissue Northern Dot Blot were purchased
from Clontech. The probe was made by PCR amplification of coding
region of UCP3 (SEQ ID NO:11). This fragment was labeled with ^{32}P and
10 used to probe the Northern blot as described in the Clontech procedures,
which are well known in the art. The blots were exposed to X-ray film
with an intensifying screen at $-70\text{ }^{\circ}\text{C}$ for times as indicated in the figure.
Figure 4A-4C is an autoradiograph which shows that UCP3 is highly
expressed in skeletal muscle as a transcript of ~ 2.4 kb (Figure 4A & B).
15 Two minor transcripts, ~ 6.0 kb and 7.5 kb are also expressed in skeletal
muscle (Figure 4A). In addition, UCP3 is also weakly expressed as a
transcript of ~ 2.4 kb in the heart. Probing with human beta-actin probe
(Figure 4C) shows that all the lanes have approximately equal amount of
total polyA RNA, indicating that detection of UCP3 only in skeletal
20 muscle and in the heart is not due to the lack of RNA in the other tissue
lanes. Also, In the brain, *ucp3* is most abundantly expressed in the
corpus callosum as a transcript of ~ 2.4 kb.

The expression pattern of UCP3 appears to be unique, because it is
abundantly and nearly exclusively expressed in skeletal muscle. Even
25 though UCP3 expression was also detected in the heart and brain, it was
found at much lower levels. Skeletal muscle is responsible for more
than half of energy expenditure at resting stage. Differences in energy
expenditure of skeletal muscle can explain most of the variation in basal
metabolic rate between individuals (Ravussin and Bogardus, 1992, *Am J*
30 *Clin Nutr* 55: 242S-245S). The proton leak was shown to account for
around one-half of the resting respiration rate of perfused rat skeletal
muscle (Rolfe and Brand, 1996, *Am J Physiol* 271: C1380-1389).
Furthermore, free fatty acids-activated uncoupling in skeletal muscle

was also observed previously (Brustovetsky et al., 1992, *FEBS Lett* 305: 15-17). Thus, UCP3 should provide a significant contribution to the uncoupling activities in skeletal muscle since it is much more strongly expressed than UCP1 and UCP2, and its activity is likely to be dependent 5 on free fatty acids.

EXAMPLE 5:

10 Characterization and Chromosomal Localization of Genes Encoding UCP3

To map the position of *ucp3* in the human genome, the primer pair 3U3F (SEQ ID NO:7) and 3U3R (SEQ ID NO:8) of *ucp3* was used to carry out PCR reactions with the 83 clones of the Stanford radiation hybrid panel 15 (Cox et al., 1990, *Science*, 250:245:250). The PCR results were scored and submitted to the Stanford Genome Center for linkage analysis. It was found that *ucp3* is located close to the marker D11S944e with a lod score of 9.4, which corresponds to the cytogenetic location of 11q13.1~11q23.3.

Radiation hybrid mapping placed this gene into a region around 20 chromosome 11q21, the same region where *ucp2* is located (Fleury et al., 1997, *Nature Genetics* 15: 269-272). Sequence analysis showed that UCP3 is 72% identical to UCP2 and 56% identical to UCP1 at the amino acid level. Hydropathy analysis showed that UCP3 has the same 25 hydrophobicity/hydrophilicity profile as UCP1 and 2. Like UCP1 and UCP2, the UCP3 protein also consists of three repeating units with each unit containing 2 transmembrane domains. Given this homology to UCP1 and UCP2, human UCP3 is predicted to encode an uncoupling protein. Two mouse bacterial artificial chromosome (BAC) clones containing mouse UCP2 were obtained using an STS in the 3' UTR of 30 mouse UCP2. After the mouse UCP3 sequence was determined, PCR with mouse UCP3-specific primers scored positive with both mouse UCP2 BAC clones. In the mouse, the UCP2 and UCP3 genes were found to be in the same BAC clone suggesting that UCP3 is located close to UCP2 on chromosome 7. Thus, UCP2 and UCP3 are located in the same

chromosomal region in both human and mouse, while human UCP1 was mapped to 4q31. The chromosomal regions where UCP2 resides are linked to obesity and hyperinsulinemia in both human and mouse, and so UCP2 was hypothesized to be a candidate gene for these diseases

5 (Taylor and Phillips, 1996, *Genomics* 34, 389-398; Fleury et al., 1997, *Nature Genetics* 15: 269-272). The close location of UCP3 to UCP2 suggests that UCP3 is also a candidate gene for obesity and hyperinsulinemia. In addition, the close homology and location between UCP2 and UCP3 suggested that the two genes arose from a gene

10 duplication event after UCP1 was separated.

Alignment of the six protein sequences of UCP1 to UCP3 of human and mouse reveals a highly clustered pattern of the conserved residues. The transmembrane domains and their immediate following sequences are much more conserved than the sequences between the

15 transmembrane domains. Moreover, each albnb motif following the first transmembrane domain of each repeat unit is perfectly conserved among the six proteins. Thus, UCP3 is a typical member of the mitochondria transport protein superfamily. UCP1 activity is inhibited by nucleotides but activated by free fatty acids. Affinity labeling and site-directed mutagenesis demonstrated that the region between

20 transmembrane domain 5 and 6 bound to nucleotides (Mayinger and Klingenberg, 1992, *Biochemistry* 31: 10536-10543; Winkler and Klingenberg, 1992, *Eur J Biochem* 203: 295-304). Particularly, deletion of the putative nucleotide binding motif (amino acid residue 261 to 269)

25 renders UCP1 resistant to nucleotide-mediated inhibition (Bouillaud et al., 1994, *EMBO J* 13, 1990-1997). Substitution of Phe 267 by a Tyr also results in higher uncoupling activity (Bouillaud et al., id.). Both UCP2 and UCP3 contain a Tyr instead of a Phe at this position, suggesting that UCP2 and UCP3 has higher basal activity. On the other hand, UCP1

30 and UCP3 both have a Thr at the position corresponding residue 264 of UCP1 whereas UCP2 has an Arg. The presence of a positively charged residue in this motif may imply a higher affinity of UCP2 for nucleotides and, consequently, increased sensitivity to nucleotide-mediated inhibition. The very C-terminus of UCP1 was shown to be important for

35 activation by fatty acids (Gonzalez-Barroso et al., 1996, *Eur J Biochem*

239: 445-450). Sequence alignments of the three UCP members, surprisingly, found that last 10 residues are not well conserved among each other at all, suggesting the activity of each UCP has different sensitivity to free fatty acids. In UCP1, change of Cys 304 to an Ala 5 results in decreased activation while change to a Ser leads to increased activation by fatty acids (Gonzalez-Barroso et al., id.). Interestingly, UCP2 contains an Ala whereas UCP3 contains a Ser at the Cys 304 position, suggesting UCP3 has higher activity than UCP2. These 10 comparisons suggest that UCP3 would be the most active among the three since UCP2 was shown to be more active than UCP1 under the same conditions (Fleury et al., 1997, *Nature Genetics* 15: 269-272; Gimeno et al., 1997, *Diabetes* 46: 900-906). In fact, expression of UCP3 in yeast reduced membrane potential more than UCP2.

15

EXAMPLE 6:
Adenovirus-Mediated Leptin Expression

All animal experiments were carried out in accordance with our 20 institutional guidance. A total of 10 age-match female *ob/ob* mice were weighed and injected through tail vein (IV) as follows: three with E1-deleted replication deficient adenoviral vector expressing leptin (Ad-leptin), three with helper-dependent adenoviral vector expressing leptin(HD-leptin), two with β -gal-expressing adenoviral vector(Ad- β -gal), and two were injected with buffer alone. The animals were then 25 monitored for weight on a daily basis and sacrificed after one week of observation. Blood was collected for each animal and serum leptin levels were determined by Linco Research Inc. (St. Charles, MO) using an RIA assay. Total RNA was isolated from skeletal muscle tissue of 30 each animal and used to prepare Northern blots. Approximately equal amounts of total RNA were loaded for each sample as estimated from the amount of ribosomal RNA in each lane. The blots were probed with human UCP3 and signals were quantified by phosphoimaging analysis (Molecular Dynamics, Sunnyvale, CA).

It has been reported that adenovirus-mediated leptin expression leads to significant reduction of body weight in ob/ob mice. Given the abundance of UCP3 in skeletal muscle, the effect of leptin treatment on UCP3 expression in skeletal muscle was tested by injecting

5 adenoviruses expressing leptin into ob/ob mice and examining UCP3 expression after one week. Injection of adenoviruses expressing leptin, either helper-dependent (HD-leptin) or first generation (Ad-leptin), led to significant weight loss (approximately 15%) after one week while injection of adenoviral vector expressing b-galactosidase (Adb-gal) had

10 no significant effect on body weight (Figure 9A). Measurement of serum leptin levels at the end of one week confirmed high levels of leptin production in mice injected with HD-leptin (26.7 ± 10 ng/ml) or Ad-leptin (21.8 ± 16.7 ng/ml) but not in mice injected with Adb-gal (1.56 ± 0.05 ng/ml) or buffer alone (2 ± 0.17 ng/ml). Wild type lean mice have leptin

15 levels at approximately 4.5 ng/ml. UCP3 levels were then checked in skeletal muscle of these animals. Mice treated with adenovectors expressing leptin, either Ad-leptin or HD-leptin, showed approximately an increase of 80% and 70%, respectively, in UCP3 RNA level (Figure 9B, $p=0.2$ vs. buffer-injected mice). In contrast, mice treated with Adb-gal

20 did not show significant change in UCP3 expression. If the average UCP3 level of animals showing weight loss (leptin-treated, $n=6$) was compared with that of animals showing no weight loss (b-galactosidase treated or untreated, $n=4$), the increase in UCP3 expression after leptin treatment was statistically significant ($p=0.01$). Thus, leptin treatment

25 leads to increased UCP3 expression in skeletal muscle in ob/ob mice.

Leptin plays a pivotal role in the regulation of food intake and energy expenditure. Leptin-deficient ob/ob mice are hyperphagic and hypometabolic, and leptin treatment led to decreased food intake and increased metabolic rate (Halaas et al., 1995, *Science* 269: 543-546, Hwa et al., 1997, *Am J Physiol* 272, R1204-1209; Hwa et al., 1996 *Horm Metab Res* 28: 659-663). These results suggest that UCP3 may be involved in the increase of metabolic rate post-leptin treatment. Leptin treatment led to increased expression of UCP2 in pancreatic islets and adipose tissue (Zhou et al., 1997). Thus, both UCP2 and UCP3 are likely to be

35 involved in the increase of metabolic rate post-leptin treatment.

EXAMPLE 7:

Isolation and Characterization of DNA Fragments
Encoding Full-Length Mouse UCP3

5

Mouse UCP3 was isolated by semi-nested PCR followed by 5' and 3' race. Three degenerate PCR primers were designed based on the conserved regions of the three uncoupling proteins: F441, 5'-CCNCTGGAYACNGCYAA-3' (SEQ ID NO:19); F755, 5'-CAGCCCACNGANGTNGT-3' (SEQ ID NO:20); and R1055, 5'-TTCACCACRTCNACNGG-3' (SEQ ID NO:21). First round PCR was carried out on mouse skeletal muscle cDNA with the primer pair F441+R1055. Second round PCR was carried out with the primer pair F755+R1055. All PCR reactions were carried out using AmpliTaq Gold (Perkin Elmer, NJ). The degenerate PCR product was cloned into the vector pCR2.1 (Invitrogen, CA) and sequenced. Analysis of the sequences identified a partial cDNA sequence that was highly homologous to human UCP3. This partial sequence were then used to isolate the full-length sequence of mouse UCP3 by 5' and 3' race using a Marathon race kit from Clontech (Clontech Laboratories, CA). DNA sequences were all determined using the ABI Prism dye terminator system on ABI 377 machines. The full length cDNA encoding mouse UCP3 (SEQ ID NO:17) is shown in Figure 6A and 6B and the amino acid sequence of mouse UCP3 (SEQ ID NO:18) is shown in Figure 7.

25

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANTS: Liu, Qingyun
Chen, Fang

10

(ii) TITLE OF INVENTION: Human Uncoupling Protein 3

(iii) NUMBER OF SEQUENCES: 21

(iv) CORRESPONDENCE ADDRESS:

15

(A) ADDRESSEE: Merck & Co., Inc.
(B) STREET: P.O. Box 2000 RY60-30
(C) CITY: Rahway
(D) STATE: NJ
(E) COUNTRY: US
(F) ZIP: 07065-0907

20

(v) COMPUTER READABLE FORM:

25

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

35

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Hand, J. Mark
(B) REGISTRATION NUMBER: 36,545
(C) REFERENCE/DOCKET NUMBER: 19959Y

40

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 732/594-3905
(B) TELEFAX: 732/594-4720

(2) INFORMATION FOR SEQ ID NO:1:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 404 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: cDNA

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	GGTGACCTAC GACATCCTCA AGGAGAAGCT GCTGGACTAC CACCTGCTCA CTGACAACTT	60
5	CCCCTGCCAC TTTGTCTCTG CCTTTGGAGC CGGCTTCTGT GCCACAGTGG TGGCATCCCC	120
	GGTGGACGTG GTGAAGACCC GGTATATGAA CTCACCTCCA GGCCAGTACT TCAGCCCCCT	180
10	CGACTGTATG ATAAAGATGG TGGCCCAGGA GCGCCACCAG CCTTCTACAA GGGATTTACA	240
	CCCTCCTTTT TGCCTTGGG ATCCTGGAAC GTGGTGATGT TCGTAACCTA TGAGCAGCTG	300
	AAACGGGCC CGTATGAAAGT CCAGATGTTA CGGGAATCAC CGTTTGAAC AAGACAAGAA	360
15	GGCCACTGGT AGCTAACGTG TCCGAAACCA GTTAAGAATG GAAG	404

(2) INFORMATION FOR SEQ ID NO:2:

	(i) SEQUENCE CHARACTERISTICS:
20	(A) LENGTH: 405 base pairs
	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: double
	(D) TOPOLOGY: linear
25	(ii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

	GGTGACCTAC GACATCCTCA AGGAGAAGCT GCTGGACTAC CACCTGCTCA CTGACAACTT	60
35	CCCCTGCCAC TTTGTCTCTG CCTTTGGAGC CGGCTTCTGT GCCACAGTGG TGGCATCCCC	120
	GGTGGACGTG GTGAAGACCC GGTATATGAA CTCACCTCCA GGCCAGTACT TCAGCCCCCT	180
	CGACTGTATG ATAAAGATGG TGGCCCAGGA GCGCCACCAG CCTTCTACAA GGGATTTACA	240
40	CCCTCCTTNT TTGCGTTGG GATCCTGAA CGTGGTGATG TTCGTAACCT ATGAGCAGCT	300
	GAAACGGGCC CTGATGAAAG TCCAGATGTT ACGGGAATCA CCGTTTGAAC CAAGACAAGA	360
45	AGGCCACTGG TAGCTAACGT GTCCGAAACCA AGTTAAGAAT GGAAG	405

(2) INFORMATION FOR SEQ ID NO:3:

	(i) SEQUENCE CHARACTERISTICS:
50	(A) LENGTH: 159 base pairs
	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: double
	(D) TOPOLOGY: linear
55	(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

5 CGAGCAGCTG AAACGGGCC TGATGAAAGT CCAGATGTTA CGGGNATCAC CGTTTGAAAC 60
 AAGACAAGAA GGCCACTGGT AGCTAACGTN TCCGAAACCA GTTAAGATTG GAAGAAAACG 120
 GTCCATCCAC GNACACATGG ACACAGACCC ACACATNTT 159

10 (2) INFORMATION FOR SEQ ID NO:4:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 484 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: cDNA

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

25 TTTTTTTTGT TCTTACTCCC ACACCTAAGG TGGAANTTCT TTTATTGAGT CATAATAATT 60
 TCCCGAGAAT TCCGAGTCCT GCTACTTTAG GTTCTTGCCC AGGAATCCAC CTCTTTCCC 120
 30 CCAAGCCCAA CAATCCTTTG AGGTACTCAT GATTGAGCGC GTGGTGGGGG GGGGTGGGA 180
 AGAGGCTGCA TGGGGGTGGG GCTCCTGTGG CTTCACGTCA TCCACTGTCA CCTCTGGTCC 240
 CCAAGTCTCT GGATCCTTTG GTCTCACCTC TAGACAACCG GCAGGGTTCA AACCTTCTTC 300
 35 CCTGGCAACT CCTCTCTGTC CCGACAAAAT CTCTCCCAAG GCATTGTCCT TGTAGTTAGA 360
 TTTACACAGA GCTTTTGCTT TTATAAAGTG CGTTCATGCC CAGCTTCTCA CTTGCATGTC 420
 40 ATAGCACCCCC TGGTGAGGTG GACAGGGAAG GGATGGCTCC CTCCATTTG TAGGAAAGTN 480
 GGGG 484

(2) INFORMATION FOR SEQ ID NO:5:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

55

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAGCTGCTGG ACTACCACCT GCTC

24

10 5 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TACTGCCCTG GAGGTGAGTT CA

22

25 (2) INFORMATION FOR SEQ ID NO:7:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

40 CCAAGCCCCAA CAATCCTTTG A

21

45 (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CCAAAGGATC CAGAGACTTG G 21

(2) INFORMATION FOR SEQ ID NO:9:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TTGTGTGGAA TTGTGAGCGG ATAAC 25

20 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CCAGGGTTTT CCCAGTCACG AC 22

35 (2) INFORMATION FOR SEQ ID NO:11:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2340 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: cDNA

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

55 TCGAACTCAC TCACCTCCCC TCTCACCTCA CTGCCCTCAC CAGCCAGCCT CTTGTCAAGT 60
 GATCAGGCTG TCAACCAACT TCTCTAGGAT AAGGTTTCAG GTCAGCCTGT GTGTATAAGA 120

	CCAGTGCCAA	GCCAGAAGCA	GCAGAGACAA	CAGTGAATGA	CAAGGAGGGG	CCATCCAATC	180					
5	CCTGCTGCCA	CCTCCTGGGA	TGGAGCCCTA	GGGAGCCCT	GTGCTGCC	TGCCGTGGCA	240					
	GGACTCACAG	CCCCACCGCT	GA	CTGAAGC	CCAGGGCTGT	GGAGCAGCTC	TCTCCTTGGA	300				
	CTCCTCTCGG	CCCTAAAGGG	ACTGGGCAGA	GCCTTCCAGG	ACTATGGTTG	GA	CTGAAGCC	360				
10	TTCAGACGTG	CCTCCCACCA	TGGCTGTGAA	GT	TGCTGGGG	GCAGGCACAG	CAGCCTGTT	420				
	TGCTGACCTC	GT	TACCTTTC	CA	CTGGACAC	AGCCAAGGTC	CGCCTGCAGA	480				
15	GA	ACCAGGGCG	GT	CCAGACGG	CCC	GGCTCGT	GCAGTACCGT	GGCGTGCTGG	540			
	GACCATGGTG	CGGACTGAGG	GT	CCCTGCAG	CCC	CTACAAT	GGGCTGGTGG	CCGGCCTGCA	600			
	GCGCCAGATG	AG	CTTCGCCT	CC	ATCCGCAT	CGGCCTTTAC	GA	CTCGTCA	AGCAGGTGTA	660		
20	CACCCCCAAA	GGCGCGGACA	ACTCCAGCCT	CA	CTACCCGG	AT	TTTGGCCG	GCTGCACCAC	720			
	AGGAGCCATG	CGGGTGACCT	GT	CCCAGCC	CA	CAGATGTG	GT	GAAGGTCC	GATTCAGGC	780		
25	CAGCATA	CAC	CTCGGGCCAT	CC	AGGAGCGA	CA	AAAATAC	AGCGGACTA	TGGACGCCTA	840		
	CAGAACCATC	GCC	AGGGAGG	AAGGAGTCAG	GGG	CCTGTGG	AAAGGAAC	TT	TGCCAACAT	900		
	CATGAGGAAT	GCT	ATCGTCA	ACT	GTGCTGA	GGT	GGTGACC	TACGACATCC	TCAAGGAGAA	960		
30	GCTGCTGGAC	TATCACCTGC	TC	ACTGACAA	CT	TCCCCTGC	CA	CTTGTCT	CTGCCTTTGG	1020		
	AGCCGGCTTC	TGTGCCACAG	TG	GTGGCCTC	CC	CGTGGAC	GT	GGTGAAGA	CCC	GGTATAT	1080	
35	GA	ACTCACCT	CC	AGGCCAGT	AC	TTCAAGCCC	CC	TGTGGCCA	GG	GGGCC	1140	
	GGAGGGCCCC	AC	AGCCTTCT	AC	AAGGGATT	TA	ACACCCTCC	TT	TTGCGTT	TGG	GATCCTG	1200
	GAACGTGGTG	AT	GTTCGTAA	C	CTATGAGCA	G	CTGAAACGG	GC	CCTGATGA	AA	GTCCAGAT	1260
40	GTTACGGAA	TC	ACCGTTTT	GA	ACAAGACA	AG	AAGGCCAC	TG	TAGCTAA	CG	TGTCCGAA	1320
	ACCAGTTAAG	AATGGAAGAA	AACGGTGCAT	CC	ACGCACAC	AT	GGACACAG	AC	CCACACAT	1380		
45	GTTTACAGAA	CT	GTGTGTTA	CT	TGTTGCTG	AT	TCAGAAA	CA	GAAGTAGA	AG	AGAGAGAGGA	1440
	TTCTGGTCTT	CA	CTGCCATG	C	CTCAAGAAC	AC	CTTGTGTT	TG	CACTGACA	AG	ATGGAAAA	1500
	TAAATTATAT	TA	ATTTTGAA	AA	CCATTAG	GC	ATGCCTAA	TAT	TTAGGCA	AG	AGAAAATA	1560
50	AACCAAGATA	GATCCATTG	GAC	AAAATGG	AAGGTTGGAG	AC	GTGTATCC	CC	GTGAAATC	1620		
	TGGTCAGATA	AT	GAATGATA	AG	CAGGAAGG	AT	GGCAAGCA	CG	GGACAGGA	GG	GGCCACACA	1680
55	ATGGAGTGGG	AG	ATCAGCCA	CG	GAGCCTGG	AG	GGACGCCA	CC	CAGCAACA	CA	GAGCTGGC	1740
	GA	CTGCAGCT	GC	ACCACATCAC	AC	ATGCATCA	TC	AGCCTATT	TG	TAATATGT	CTGCCACAGA	1800

	GAGTCCTTG GGATTCTAGG AAACCCAAGG ACAAGAGAA AAAACTAGAG CCTGTGCTAA	1860
5	AGAACCTGC TGGGCCATG TGAGGCTGGG GTCGTAAATA TTCCCCGACG AACTGAAGA	1920
	ATCAAGAGGG CAGCCCCAC TTCTCCTACA AAATGGAGGG AGCCATCCCT TCCCTGTCCA	1980
	CCTCACCAAGG GGTGCTATGA CATGCAAGTG AGAAGCTGGG CATGAACGCA CTTTATAAAA	2040
10	GCAAAAGCTC TGTGTAAATC TAACTACAAG GACAATGCCT TGGGAGAGAT TTTGTCGGGA	2100
	CAGAGAGGAG TTGCCAGGGA AGAAGGTTTG AAAGATAACGG TTGTCTAGAG GTGAGACCAA	2160
15	AGGATCCAGA GACTTGGGGA CCAGAGGTGA CAGTGGATGA CGTGAAGCCA CAGGAGCCCC	2220
	ACCCCCATGC AGCTTTTCC CCACCCCCC CACCACGCGC TCAATCATGA GTACCTCAAA	2280
	GGATTGTTGG GCTTGGGGGA AAAGAGGTGG ATTCTGGGC AAGAACCTAA AGTAGCAGGA	2340

20

(2) INFORMATION FOR SEQ ID NO:12:

25

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 312 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

40

Met	Val	Gly	Leu	Lys	Pro	Ser	Asp	Val	Pro	Pro	Thr	Met	Ala	Val	Lys
1															15

	5							10							
--	---	--	--	--	--	--	--	----	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

45

Phe	Leu	Gly	Ala	Gly	Thr	Ala	Ala	Cys	Phe	Ala	Asp	Leu	Val	Thr	Phe
20														30	

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Pro	Leu	Asp	Thr	Ala	Lys	Val	Arg	Leu	Gln	Ile	Gln	Gly	Glu	Asn	Gln
35													45		

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

50

Ala	Val	Gln	Thr	Ala	Arg	Leu	Val	Gln	Tyr	Arg	Gly	Val	Leu	Gly	Thr
50													60		

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Ile	Leu	Thr	Met	Val	Arg	Thr	Glu	Gly	Pro	Cys	Ser	Pro	Tyr	Asn	Gly
65													75		80

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

55

Leu	Val	Ala	Gly	Leu	Gln	Arg	Gln	Met	Ser	Phe	Ala	Ser	Ile	Arg	Ile
85													90		95

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Gly	Leu	Tyr	Asp	Ser	Val	Lys	Gln	Val	Tyr	Thr	Pro	Lys	Gly	Ala	Asp
100													110		

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

	Asn Ser Ser Leu Thr Thr Arg Ile Leu Ala Gly Cys Thr Thr Gly Ala
	115 120 125
5	Met Ala Val Thr Cys Ala Gln Pro Thr Asp Val Val Lys Val Arg Phe
	130 135 140
	Gln Ala Ser Ile His Leu Gly Pro Ser Arg Ser Asp Arg Lys Tyr Ser
	145 150 155 160
10	Gly Thr Met Asp Ala Tyr Arg Thr Ile Ala Arg Glu Glu Gly Val Arg
	165 170 175
	Gly Leu Trp Lys Gly Thr Leu Pro Asn Ile Met Arg Asn Ala Ile Val
	180 185 190
15	Asn Cys Ala Glu Val Val Thr Tyr Asp Ile Leu Lys Glu Lys Leu Leu
	195 200 205
20	Asp Tyr His Leu Leu Thr Asp Asn Phe Pro Cys His Phe Val Ser Ala
	210 215 220
	Phe Gly Ala Gly Phe Cys Ala Thr Val Val Ala Ser Pro Val Asp Val
	225 230 235 240
25	Val Lys Thr Arg Tyr Met Asn Ser Pro Pro Gly Gln Tyr Phe Ser Pro
	245 250 255
	Leu Asp Cys Met Ile Lys Met Val Ala Gln Glu Gly Pro Thr Ala Phe
	260 265 270
30	Tyr Lys Gly Phe Thr Pro Ser Phe Leu Arg Leu Gly Ser Trp Asn Val
	275 280 285
35	Val Met Phe Val Thr Tyr Glu Gln Leu Lys Arg Ala Leu Met Lys Val
	290 295 300
	Gln Met Leu Arg Glu Ser Pro Phe
	305 310
40	(2) INFORMATION FOR SEQ ID NO:13:
	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 27 base pairs
	(B) TYPE: nucleic acid
45	(C) STRANDEDNESS: single
	(D) TOPOLOGY: linear
	(ii) MOLECULE TYPE: other nucleic acid
	(A) DESCRIPTION: /desc = "oligonucleotide"
50	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
55	CATAGAATTC CAGGACTATG GTTGGAC

(2) INFORMATION FOR SEQ ID NO:14:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CATTCTCGAG CTACCAGTGG CCTTCTTG

28

20 (2) INFORMATION FOR SEQ ID NO:15:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

35 CCCGGATCGG ACTACTAGCA

20

(2) INFORMATION FOR SEQ ID NO:16:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "oligonucleotide"

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

55 GGGGGGAGGG CGTGAATGTA A

21

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1658 base pairs
- (B) TYPE: nucleic acid
- 5 (C) STRANDEDNESS: double
- (D) TOPOLOGY: both

(ii) MOLECULE TYPE: cDNA

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

15	CCAGGAACAG CAGAGACAAC AGTGAATGGT GAGGCCCGC CGTCAGATCC TGCTGCTACC	60
	TAATGGAGTG GATCCTTAGG GTGGCCCTGC ACTACCCAAC CTTGGCTAGA CGCACAGCTT	120
20	CCTCCCTGAA CTGAAGCAAA AGATTGCCAG GCAAGCTCTC TCCTCGGACC TCCATAGGCA	180
	GCAAAGGAAC CAGGCCATT CCCCGGGACC ATGGTTGGAC TTCAGCCCTC CGAAGTGCCT	240
	CCCACAAACGG TTGTGAAGTT CCTGGGGGCC GGCACTGCGG CCTGTTTGCG GGACCTCCTC	300
25	ACTTTTCCCC TGGACACCGC CAAGGTCCGT CTGCAGATCC AAGGGGAGAA CCCAGGGCT	360
	CAGAGCGTGC AGTACCGCGG TGTGCTGGGT ACCATCCTGA CTATGGTGCG CACAGAGGGT	420
30	CCCCGCAGCC CCTACAGCGG ACTGGTCGCT GGCCCTGCACC GCCAGATGAG TTTTGCCTCC	480
	ATTCAATTG GCCTCTACGA CTCTGTCAAG CAGTTCTACA CCCCAAGGG AGCGGACCAC	540
	TCCAGCGTCG CCATCAGGAT TCTGGCAGGC TGCACGACAG GAGCCATGGC AGTGACCTGC	600
35	GCCCAGCCA CGGATGTGGT GAAGGTCCGA TTTCAAGCCA TGATACGCCT GGGAACTGGA	660
	GGAGAGAGGA AATACAGAGG GACTATGGAT GCCTACAGAA CCATGCCAG GGAGGAAGGA	720
40	GTCAGGGGCC TGTGGAAAGG GACTTGGCCC AACATCACAA GAAATGCCAT TGTCAACTGT	780
	GCTGAGATGG TGACCTACGA CATCATCAAG GAGAAGTTGC TGGAGTCTCA CCTGTTTACT	840
	GACAACTTCC CCTGTCACTT TGTCTCTGCC TTTGGAGCTG GCTTCTGTGC CACAGTGGTG	900
45	GCCTCCCCGG TGGATGTGGT AAAGACCGA TACATGAACCG CTCCCTAGG CAGGTACCGC	960
	AGCCCTCTGC ACTGTATGCT GAAGATGGTG GCTCAGGAGG GACCCACGGC CTTCTACAA	1020
50	GGATTTGTGC CCTCCTTCT CGGTCTGGGA GCTTGGAACG TGATGATGTT TGTAACATAT	1080
	GAGCAACTGA AGAGGGCCTT AATGAAAGTC CAGGTACTGC GGGAACTCC GTTTGAACA	1140
	AGGCAAGCAG GCTGCCTGGA ACAGAACAAA GCGTCTCTGC CCTGGGGACA CAGGCCACAA	1200
55	CGGTCCAGAA CCCTGCACTG CTGCTGACAC GAGAAACTGA ACTAAAAGAG GAGAGTTTA	1260

GTCCTCCGTG TTTCGTCCTA AAACACCTCT GTTTTGCACT GACCTGATGG GAAATAAATT 1320
 ATATTAATTT TTAAACCCCTT TCCGGTTGGA TGCCTAACAT TTAGGCAAGA GACAACAAAG 1380
 5 AAAACCAGAG TCAACTCCCT TGAAATGTAG GAATAAAGGA TGCATAATAA ACAGGAAAGG 1440
 CACAGGTTTT GAGAAGATCA GCCCACAGTG TTGTCCTTGA ATCAAACAAA ATGGTCGGAG 1500
 10 GAACCCTTCG GGTCAGCAC AAAGAGGTGA CTACAGCCTT TTGGTCACCA GATGACTCCG 1560
 CCCTTTGTGTA ATGAGTCTGC CAAGTAGACT CTATCAAGAT TCTGGGGAAA GGAGAAAGAA 1620
 CACATTGACC TGCCCGGGCG GCCGCTCGAG CCCTATGA 1658

15 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 308 amino acids
 (B) TYPE: amino acid
 20 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
 25 (A) DESCRIPTION: /desc = "oligonucleotide"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
 Met Val Gly Leu Gln Pro Ser Glu Val Pro Pro Thr Thr Val Val Lys
 1 5 10 15

35 Phe Leu Gly Ala Gly Thr Ala Ala Cys Phe Ala Asp Leu Leu Thr Phe
 20 25 30

Pro Leu Asp Thr Ala Lys Val Arg Leu Gln Ile Gln Gly Glu Asn Pro
 35 40 45

40 Gly Ala Gln Ser Val Gln Tyr Arg Gly Val Leu Gly Thr Ile Leu Thr
 50 55 60

Met Val Arg Thr Glu Gly Pro Arg Ser Pro Tyr Ser Gly Leu Val Ala
 45 65 70 75 80

Gly Leu His Arg Gln Met Ser Phe Ala Ser Ile Arg Ile Gly Leu Tyr
 85 90 95

50 Asp Ser Val Lys Gln Phe Tyr Thr Pro Lys Gly Ala Asp His Ser Ser
 100 105 110

Val Ala Ile Arg Ile Leu Ala Gly Cys Thr Thr Gly Ala Met Ala Val
 115 120 125

55 Thr Cys Ala Gln Pro Thr Asp Val Val Lys Val Arg Phe Gln Ala Met
 130 135 140

Ile Arg Leu Gly Thr Gly Gly Glu Arg Lys Tyr Arg Gly Thr Met Asp
 145 150 155 160

5 Ala Tyr Arg Thr Ile Ala Arg Glu Glu Gly Val Arg Gly Leu Trp Lys
 165 170 175

Gly Thr Trp Pro Asn Ile Thr Arg Asn Ala Ile Val Asn Cys Ala Glu
 180 185 190

10 Met Val Thr Tyr Asp Ile Ile Lys Glu Lys Leu Leu Glu Ser His Leu
 195 200 205

15 Phe Thr Asp Asn Phe Pro Cys His Phe Val Ser Ala Phe Gly Ala Gly
 210 215 220

Phe Cys Ala Thr Val Val Ala Ser Pro Val Asp Val Val Lys Thr Arg
 225 230 235 240

20 Tyr Met Asn Ala Pro Leu Gly Arg Tyr Arg Ser Pro Leu His Cys Met
 245 250 255

Leu Lys Met Val Ala Gln Glu Gly Pro Thr Ala Phe Tyr Lys Gly Phe
 260 265 270

25 Val Pro Ser Phe Leu Arg Leu Gly Ala Trp Asn Val Met Met Phe Val
 275 280 285

30 Thr Tyr Glu Gln Leu Lys Arg Ala Leu Met Lys Val Gln Val Leu Arg
 290 295 300

Glu Ser Pro Phe
 305

35 (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: other nucleic acid
 (A) DESCRIPTION: /desc = "degenerate oligonucleotide"

45

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
 CCNCTGGAYA CNGCYAA

17

(2) INFORMATION FOR SEQ ID NO:20:

55 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "degenerate oligonucleotide"

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CAGCCCACNG ANGTNGT

17

15 (2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "degenerate oligonucleotide"

25

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TTCACCACRT CNACNGG

17

WHAT IS CLAIMED IS:

1. A purified DNA molecule encoding a human uncoupling protein 3 which comprises the nucleotide sequence
5 TCGAACTCAC TCACCTCCCC TCTCACCTCA CTGCCCTCAC CAGCCAGCCT
CTTGTCAAGT GATCAGGCTG TCAACCAAAT TCTCTAGGAT AAGGTTTCAG
GTCAGCCTGT GTGTATAAGA CCAGTGCCAA GCCAGAAGCA GCAGAGACAA
CAGTGAATGA CAAGGAGGGG CCATCCAATC CCTGCTGCCA CCTCCTGGGA
TGGAGCCCTA GGGAGCCCT GTGCTGCCCT TGCCGTGGCA GGACTCACAG
10 CCCCACCGCT GCACTGAAGC CCAGGGCTGT GGAGCAGCTC TCTCCTTGGGA
CTCCTCTCGG CCCTAAAGGG ACTGGGCAGA GCCTTCCAGG ACTATGGTTG
GACTGAAGCC TTCAGACGTG CCTCCCACCA TGGCTGTGAA GTTCCTGGGG
GCAGGGCACAG CAGCCTGTTT TGCTGACCTC GTTACCTTTC CACTGGACAC
AGCCAAGGTC CGCCTGCAGA TCCAGGGGA GAACCAGGCG GTCCAGACGG
15 CCCGGCTCGT GCAGTACCGT GGCGTGCTGG GCACCATCCT GACCATGGTG
CGGACTGAGG GTCCCTGCAG CCCCTACAAT GGGCTGGTGG CGGGCCTGCA
GCGCCAGATG AGCTTCGCCT CCATCCGCAT CGGCCTTAC GACTCCGTCA
AGCAGGTGTA CACCCCCAAA GGCGCGGACA ACTCCAGCCT CACTACCCGG
ATTTTGGCCG GCTGCACCAC AGGAGCCATG GCGGTGACCT GTGCCAGGCC
20 CACAGATGTG GTGAAGGTCC GATTTCAGGC CAGCATAACAC CTCGGGCCAT
CCAGGAGCGA CAGAAAATAC AGCGGGACTA TGGACGCCTA CAGAACCATC
GCCAGGGAGG AAGGAGTCAG GGGCCTGTGG AAAGGAACCT TGCCCAACAT
CATGAGGAAT GCTATCGTCA ACTGTGCTGA GGTGGTGACC TACGACATCC
TCAAGGAGAA GCTGCTGGAC TATCACCTGC TCACTGACAA CTTCCCTGC
25 CACTTTGTCT CTGCCTTGG AGCCGGCTTC TGTGCCACAG TGGTGGCCTC
CCCGGTGGAC GTGGTGAAGA CCCGGTATAT GAACTCACCT CCAGGCCAGT
ACTTCAGCCC CCTCGACTGT ATGATAAAAGA TGGTGGCCCA GGAGGGCCCC
ACAGCCTTCT ACAAGGGATT TACACCCTCC TTTTGCGTT TGGGATCCTG
GAACGTGGTG ATGTTCGTAA CCTATGAGCA GCTGAAACGG GCCCTGATGA
30 AAGTCCAGAT GTTACGGAA TCACCGTTTT GAACAAGACA AGAAGGCCAC
TGGTAGCTAA CGTGTCCGAA ACCAGTTAAG AATGGAAGAA AACGGTGCAT
CCACGCACAC ATGGACACAG ACCCACACAT GTTACAGAA CTGTTGTTA
CTTGTGCTG ATTCAAGAAA CAGAAGTAGA AGAGAGAGGA TTCTGGTCTT
CACTGCCATG CCTCAAGAAC ACCTTTGTTT TGCACTGACA AGATGGAAAA
35 TAAATTATAT TAATTTTGA AACCCATTAG GCATGCCTAA TATTTAGGCA

AGAGAAAATA AACCAAGATA GATCCATTG GACAAAATGG AAGGTTGGAG
 ACGTGTATCC CCGTCAAATC TGGTCAGATA ATGAATGATA AGCAGGAAGG
 ATGGCAAGCA CGGGACAGGA GGGGCCACA ATGGAGTGGG AGATCAGCCA
 CGGAGCCTGG AGGGACGCCA CCCAGCAACA CAGAGCTGGC GACTGCAGCT
 5 GCACCATCAC ACATGCATCA TCAGCCTATT TGTAATATGT CTGCCACAGA
 GAGTCCTTG GGATTCTAGG AAACCCAAGG AACAAAGAGAA AAAACTAGAG
 CCTGTGCTAA AGAAGCCTGC TGGGCCATG TGAGGCTGGG GTCGTAAATA
 TTCCCCGACG ACACTGAAGA ATCAAGAGGG CAGCCCCCAC TTCTCCTACA
 AAATGGAGGG AGCCATCCCT TCCCTGTCCA CCTCACCAAGG GGTGCTATGA
 10 CATGCAAGTG AGAAGCTGGG CATGAACGCCA CTTTATAAAA GCAAAAGCTC
 TGTGTAAATC TAACTACAAG GACAATGCCT TGGGAGAGAT TTTGTCGGGA
 CAGAGAGGAG TTGCCAGGAG AGAAGGTTTG AAAGATACGG TTGTCTAGAG
 GTGAGACCAA AGGATCCAGA GACTTGGGA CCAGAGGTGA CAGTGGATGA
 CGTGAAGCCA CAGGAGCCCC ACCCCCCATGC AGCTTTTCC CCACCCCCC
 15 CACCACGCGC TCAATCATGA GTACCTCAAA GGATTGTTGG GCTTGGGGGA
 AAAGAGGTGG ATTCTGGGC AAGAACCTAA AGTAGCAGGA,
 disclosed as SEQ ID NO:11.

2. A DNA molecule of claim 1 which comprises from
 20 about nucleotide 344 to about nucleotide 1282 of SEQ ID NO:11.

3. A purified DNA molecule encoding human
 uncoupling protein 3 wherein said DNA molecule encodes a protein
 comprising the amino acid sequence
 25 MVGLKPSDVPPTMAVKFLGAGTAACFADLVTPLDTAKVRLQIQGENQAVQTARLVQYR
 GVLGTILTMVRTEGPCSPYNGLVAGLQRQMSFASIRIGLYDSVKQVYTPKGADNSSLTT
 RILAGCTTGAMAVTCAQPTDVVKVRFQASIHLGPSRSDRKYSGTMDAYRTIAREEGVRG
 LWKGTLPNIMRNAIVNCAEVVTYDILKEKLLDYHLLTDNFPCHFVSAFGAGFCATVVAS
 PVDVVKTRYMNSPPGQYFSPLDCMIKMVAQEGPTAFYKGFTPSFLRLGSWNVVMFVTYE
 30 QLKRALMKVQMLRESPF, as set forth in three-letter abbreviation in SEQ ID
 NO:12.

4. An expression vector for the expression of a human
 uncoupling 3 protein in a recombinant host cell wherein said expression
 35 vector comprises the DNA molecule of claim 1.

5. An expression vector of claim 4 which is a eukaryotic expression vector.
- 5 6. An expression vector of claim 4 which is a prokaryotic expression vector.
- 10 7. A host cell which expresses a recombinant human uncoupling 3 protein wherein said host cell contains the expression vector of claim 4.
- 15 8. A host cell which expresses a recombinant human uncoupling 3 protein wherein said host cell contains the expression vector of claim 5.
- 20 9. A host cell which expresses a recombinant human uncoupling protein 3 wherein said host cell contains the expression vector of claim 6.
- 25 10. A host cell of claim 7 wherein said human uncoupling protein 3 is overexpressed from said expression vector.
11. A host cell of claim 8 wherein said human uncoupling protein 3 is overexpressed from said expression vector.
- 25 12. A host cell of claim 9 wherein said human uncoupling protein 3 is overexpressed from said expression vector.
- 30 13. A subcellular membrane fraction obtained from the host cell of claim 10 which contains recombinant human uncoupling protein 3.
- 35 14. A subcellular membrane fraction obtained from the host cell of claim 11 which contains recombinant human uncoupling protein 3 .

15. A subcellular membrane fraction obtained from the host cell of claim 12 which contains recombinant human uncoupling protein 3.

5 16. A purified DNA molecule which consists of the nucleotide sequence

TCGAACTCAC TCACCTCCCC TCTCACCTCA CTGCCCTCAC CAGCCAGCCT
CTTGTCAAGT GATCAGGCTG TCAACCAAAT TCTCTAGGAT AAGGTTTCAG
GTCAGCCTGT GTGTATAAGA CCAGTGCCAA GCCAGAAGCA GCAGAGACAA
10 CAGTGAATGA CAAGGAGGGG CCATCCAATC CCTGCTGCCA CCTCCTGGGA
TGGAGCCCTA GGGAGCCCT GTGCTGCCCT TGCCGTGGCA GGACTCACAG
CCCCACCGCT GCACTGAAGC CCAGGGCTGT GGAGCAGCTC TCTCCTTGGA
CTCCTCTCGG CCCTAAAGGG ACTGGGCAGA GCCTTCCAGG ACTATGGTTG
GACTGAAGCC TTCAGACGTG CCTCCCACCA TGGCTGTGAA GTTCCTGGGG
15 GCAGGGCACAG CAGCCTGTT TGCTGACCTC GTTACCTTTC CACTGGACAC
AGCCAAGGTC CGCCTGCAGA TCCAGGGGGA GAACCAGGCG GTCCAGACGG
CCCGGCTCGT GCAGTACCGT GGCGTGCTGG GCACCATCCT GACCATGGTG
CGGACTGAGG GTCCCTGCAG CCCCTACAAT GGGCTGGTGG CGGGCCTGCA
GCGCCAGATG AGCTTCGCCT CCATCCGCAT CGGCCTTAC GACTCCGTCA
20 AGCAGGGTGT ACCCCCAAAG GCGCGGACA ACTCCAGCCT CACTACCCGG
ATTTTGGCCG GCTGCACCAC AGGAGCCATG GCGGTGACCT GTGCCAGCC
CACAGATGTG GTGAAGGTCC GATTTCAGGC CAGCATAACAC CTCGGGCCAT
CCAGGAGCGA CAGAAAATAC AGCGGGACTA TGGACGCCTA CAGAACCATC
GCCAGGGAGG AAGGAGTCAG GGGCCTGTGG AAAGGAACTT TGCCCAACAT
25 CATGAGGAAT GCTATCGTCA ACTGTGCTGA GGTGGTGACC TACGACATCC
TCAAGGAGAA GCTGCTGGAC TATCACCTGC TCACTGACAA CTTCCCTG
CACTTTGTCT CTGCCTTGG AGCCGGCTTC TGTGCCACAG TGGTGGCCTC
CCCGGTGGAC GTGGTGAAGA CCCGGTATAT GAACTCACCT CCAGGCCAGT
ACTTCAGCCC CCTCGACTGT ATGATAAAAGA TGGTGGCCCA GGAGGGCCCC
30 ACAGCCTTCT ACAAGGGATT TACACCCTCC TTTTTGCGTT TGGGATCCTG
GAACGTGGTG ATGTTCGTAA CCTATGAGCA GCTGAAACGG GCCCTGATGA
AAGTCCAGAT GTTACGGGAA TCACCGTTTT GAACAAGACA AGAAGGCCAC
TGGTAGCTAA CGTGTCCGAA ACCAGTTAAG AATGGAAGAA AACGGTGCAT
CCACGCACAC ATGGACACAG ACCCACACAT GTTACAGAA CTGTGTGTTA
35 CTTGTTGCTG ATTCAAGAAA CAGAAGTAGA AGAGAGAGGA TTCTGGTCTT

CACTGCCATG CCTCAAGAAC ACCTTTGTTT TGCAC TGACAGACA AGATGGAAAA
 TAAATTATAT TAATTTTGAA ACCCATTAG GCATGCCTAA TATTTAGGCA
 AGAGAAAATA AACCAAGATA GATCCATTG GACAAAATGG AAGGTTGGAG
 ACGTGTATCC CCGTGAATC TGTCAGATA ATGAATGATA AGCAGGAAGG
 5 ATGGCAAGCA CGGGACAGGA GGGGCCACA ATGGAGTGGG AGATCAGCCA
 CGGAGCCTGG AGGGACGCCA CCCAGCAACA CAGAGCTGGC GACTGCAGCT
 GCACCATCAC ACATGCATCA TCAGCCTATT TGTAATATGT CTGCCACAGA
 GAGTCCTTG GGATTCTAGG AAACCCAAGG AACAAAGAGAA AAAACTAGAG
 CCTGTGCTAA AGAAGCCTGC TGGGCCATG TGAGGCTGGG GTCGTAAATA
 10 TTCCCCGACG AACTGAAAGA ATCAAGAGGG CAGCCCCAC TTCTCCTACA
 AAATGGAGGG AGCCATCCCT TCCCTGTCCA CCTCACCAAGG GGTGCTATGA
 CATGCAAGTG AGAAGCTGGG CATGAACGCA CTTTATAAAA GCAAAAGCTC
 TGTGTAAATC TAACTACAAG GACAATGCCT TGGGAGAGAT TTTGTCGGGA
 CAGAGAGGAG TTGCCAGGGA AGAAGGTTTG AAAGATACGG TTGTCTAGAG
 15 GTGAGACCAA AGGATCCAGA GACTTGGGA CCAGAGGTGA CAGTGGATGA
 CGTGAAGCCA CAGGAGCCCC ACCCCCCATGC AGCTTTTCC CCACCCCCC
 CACCACGCGC TCAATCATGA GTACCTCAAA GGATTGTTGG GCTTGGGGGA
 AAAGAGGTGG ATTCTGGGC AAGAACCTAA AGTAGCAGGA,
 disclosed as SEQ ID NO:11.

20 17. A purified DNA molecule encoding a human
 uncoupling protein 3 wherein said DNA molecule encodes a protein
 consisting of the amino acid sequence
 MVGLKPSDVPPTMAVKFLGAGTAACFADLVTPLDTAKVRLQIQGENQAVQTARLVQYR
 25 GVLGTLTMVRTEGPCSPYGLVAGLQRQMSFASIRIGLYDSVKQVTPKGADNSSLTT
 RILAGCTTGAMAVTCAQPTDVVKVRFQASIHLGPSRSDRKYSGTMDAYRTIAREEGVRG
 LWKGTLPNIMRNAIVNCAEVVTDILKEKLLDYHLLTDNFPCHFVSAFGAGFCATVVAS
 PVDVVKTRYMNSPPGQYFSPLDCMIKMVAQEGPTAFYKGFTPSFLRLGSWNVVMFVTYE
 QLKRALMKVQMLRESPF,
 30 as set forth in three-letter abbreviation in SEQ ID NO:12.

18. A process for the expression of a human uncoupling protein 3 in a recombinant host cell, comprising:

(a) transfecting the expression vector of claim 4 into a suitable host cell; and,

5 (b) culturing the host cells of step (a) under conditions which allow expression of the human uncoupling protein from the expression vector.

19. An expression vector for the expression of a human uncoupling protein 3 in a recombinant host cell wherein said expression 10 vector comprises the DNA molecule of claim 16.

20. A purified DNA molecule encoding a mouse uncoupling protein which comprises the nucleotide sequence

CCAGGAACAG CAGAGACAAAC AGTGAATGGT GAGGCCGGC CGTCAGATCC
15 TGCTGCTACC TAATGGAGTG GATCCTTAGG GTGCCCTGC ACTACCCAAC
CTTGGCTAGA CGCACAGCTT CCTCCCTGAA CTGAAGCAAAG ATTGCCAG
GCAAGCTCTC TCCTCGGACC TCCATAGGCA GCAAAGGAAC CAGGCCATT
CCCCGGGACC ATGGTTGGAC TTCAGCCCTC CGAAGTGCCT CCCACAACGG
TTGTGAAGTT CCTGGGGGCC GGCACTGCGG CCTGTTTGC GGACCTCCTC
20 ACTTTCCCC TGGACACCGC CAAGGTCCGT CTGCAGATCC AAGGGGAGAA
CCCAGGGCT CAGAGCGTGC AGTACCGCGG TGTGCTGGGT ACCATCCTGA
CTATGGTGCG CACAGAGGGT CCCCCGAGCC CCTACAGCGG ACTGGTCGCT
GGCCTGCACC GCCAGATGAG TTTTGCCTCC ATTGAATTG GCCTCTACGA
CTCTGTCAAG CAGTTCTACA CCCCCAAGGG AGCGGACCAC TCCAGCGTCG
25 CCATCAGGAT TCTGGCAGGC TGCACGACAG GAGCCATGGC AGTACCTGC
GCCAGCCCA CGGATGTGGT GAAGGTCCGA TTTCAAGCCA TGATACGCCT
GGGAAGTGGGA GGAGAGAGGA AATACAGAGG GACTATGGAT GCCTACAGAA
CCATGCCAG GGAGGAAGGA GTCAGGGGCC TGTGGAAAGG GACTTGGCCC
AACATCACAA GAAATGCCAT TGTCAACTGT GCTGAGATGG TGACCTACGA
30 CATCATCAAG GAGAAGTTGC TGGAGTCTCA CCTGTTTACT GACAACCTCC
CCTGTCACCT TGTCTCTGCC TTTGGAGCTG GCTTCTGTGC CACAGTGGTG
GCCTCCCCGG TGGATGTGGT AAAGACCCGA TACATGAACG CTCCCTAGG
CAGGTACCGC AGCCCTCTGC ACTGTATGCT GAAGATGGTG GCTCAGGAGG
GACCCACGGC CTTCTACAAA GGATTGTGC CCTCCTTCT GCGTCTGGGA
35 GCTTGGAACG TGATGATGTT TGTAACATAT GAGCAACTGA AGAGGGCCTT

AATGAAAGTC CAGGTACTGC GGGAACTCCTC GTTTGAAACA AGGCAAGCAG
 GCTGCCTGGA ACAGAACAAA GCGTCTCTGC CCTGGGGACA CAGGCCACA
 CGGTCCAGAA CCCTGCACTG CTGCTGACAC GAGAAACTGA ACTAAAAGAG
 GAGAGTTTTA GTCCTCCGTG TTTCGTCCTA AAACACCTCT GTTTGCACT
 5 GACCTGATGG GAAATAAATT ATATTAATTT TTAAACCCCTT TCCGGTTGGA
 TGCCTAACAT TTAGGCAAGA GACAACAAAG AAAACCAGAG TCAACTCCCT
 TGAAATGTAG GAATAAAGGA TGCATAATAA ACAGGAAAGG CACAGGTTTT
 GAGAAGATCA GCCCACAGTG TTGTCCTTGA ATCAAACAAA ATGGTCGGAG
 10 GAACCCCTCG GGTCAGCAC AAAGAGGTGA CTACAGCCTT TTGGTCACCA
 15 GATGACTCCG CCCCTTGTA ATGAGTCTGC CAAGTAGACT CTATCAAGAT
 TCTGGGGAAA GGAGAAAGAA CACATTGACC TGCCCGGGCG GCCGCTCGAG
 CCCTATGA, disclosed as SEQ ID NO:17.

21. A DNA molecule of claim 20 which comprises from
 15 about nucleotide 211 to about nucleotide 1137 of SEQ ID NO:17.

22. A purified DNA molecule encoding mouse
 uncoupling protein 3 wherein said DNA molecule encodes a protein
 comprising the amino acid sequence, MVGLQPSEVP PTTVVVKFLGA
 20 GTAACFADLL TFPLDTAKVR LQIQGENPGA QSVQYRGVLG TILTMVRTEG
 PRSPYSGLVA GLHRQMSFAS IRIGLYDSVK QFYTPKGADH SSVAIRILAG
 CTTGAMAVTC AQPTDVVKVR FQAMIRLGTG GERKYRGTM D YRTIAREEG
 VRGLWKGTWP NITRNAIVNC AEMVTYDIIK EKLLESHLFT DNFPCHFVSA
 FGAGFCATVV ASPVDVVKTR YMNAPlGRYR SPLHCMALKMV AQEGPTAFYK
 25 GFVPSFLRLG AWNVMMFVTY EQLKRALMKV QVLRESPF*, as set forth in
 three-letter abbreviation in SEQ ID NO:18.

23. An expression vector for the expression of a mouse
 uncoupling protein 3 in a recombinant host cell wherein said expression
 30 vector comprises the DNA molecule of claim 20.

24. An expression vector of claim 23 which is a
 eukaryotic expression vector.

25. An expression vector of claim 23 which is a prokaryotic expression vector.

26. A host cell which expresses a recombinant mouse uncoupling protein 3 wherein said host cell contains the expression vector of claim 23.

27. A host cell which expresses a recombinant mouse uncoupling 3 protein wherein said host cell contains the expression vector of claim 24.

28. A host cell which expresses a recombinant mouse uncoupling protein 3 wherein said host cell contains the expression vector of claim 25.

15 29. A host cell of claim 26 wherein said mouse uncoupling protein 3 is overexpressed from said expression vector.

20 30. A host cell of claim 27 wherein said mouse uncoupling protein 3 is overexpressed from said expression vector.

31. A host cell of claim 28 wherein said mouse uncoupling protein 3 is overexpressed from said expression vector.

25 32. A subcellular membrane fraction obtained from the host cell of claim 29 which contains recombinant mouse uncoupling protein 3.

30 33. A subcellular membrane fraction obtained from the host cell of claim 30 which contains recombinant mouse uncoupling protein 3.

35 34. A subcellular membrane fraction obtained from the host cell of claim 31 which contains recombinant mouse uncoupling protein 3.

35. A purified DNA molecule which consists of the nucleotide sequence,

CCAGGAACAG CAGAGACAAAC AGTGAATGGT GAGGCCCGGC CGTCAGATCC
5 TGCTGCTACC TAATGGAGTG GATCCTTAGG GTGGCCCTGC ACTACCCAAC
CTTGGCTAGA CGCACAGCTT CCTCCCTGAA CTGAAGCAAA AGATTGCCAG
GCAAGCTCTC TCCTCGGACC TCCATAGGCA GCAAAGGAAC CAGGCCATT
CCCCGGGACC ATGGTTGGAC TTCAGCCCTC CGAAGTGCCT CCCACAACGG
TTGTGAAGTT CCTGGGGGCC GGCACTGCGG CCTGTTTGC GGACCTCCTC
10 ACTTTTCCCC TGGACACCGC CAAGGTCCGT CTGCAGATCC AAGGGGAGAA
CCCAGGGCT CAGAGCGTGC AGTACCGCGG TGTGCTGGGT ACCATCCTGA
CTATGGTGCG CACAGAGGGT CCCCGCAGCC CCTACAGCGG ACTGGTCGCT
GGCCTGCACC GCCAGATGAG TTTTGCCTCC ATTGAATTG GCCTCTACGA
CTCTGTCAAG CAGTTCTACA CCCCCAAGGG AGCGGACCAC TCCAGCGTCG
15 CCATCAGGAT TCTGGCAGGC TGACAGACAG GAGCCATGGC AGTACCTGC
GCCAGCCCA CGGATGTGGT GAAGGTCCGA TTTCAAGCCA TGATACGCCT
GGGAACTGGA GGAGAGAGGA AATACAGAGG GACTATGGAT GCCTACAGAA
CCATGCCAG GGAGGAAGGA GTCAGGGGCC TGTGGAAAGG GACTTGGCCC
AACATCACAA GAAATGCCAT TGTCAACTGT GCTGAGATGG TGACCTACGA
20 CATCATCAAG GAGAAGTTGC TGGAGTCTCA CCTGTTTACT GACAACCTCC
CCTGTCACCT TGTCTCTGCC TTTGGAGCTG GCTTCTGTGC CACAGTGGTG
GCCTCCCCGG TGGATGTGGT AAAGACCCGA TACATGAACG CTCCCTAGG
CAGGTACCGC AGCCCTCTGC ACTGTATGCT GAAGATGGTG GTCAGGAGG
GACCCACGGC CTTCTACAAA GGATTTGTGC CCTCCTTCT GCGTCTGGGA
25 GCTTGGAACG TGATGATGTT TGTAACATAT GAGCAACTGA AGAGGGCCTT
AATGAAAGTC CAGGTACTGC GGGAACTCTCC GTTTGAACA AGGCAAGCAG
GCTGCCTGGA ACAGAACAAA GCGTCTCTGC CCTGGGGACA CAGGCCACA
CGGTCCAGAA CCCTGCACTG CTGCTGACAC GAGAAACTGA ACTAAAAGAG
GAGAGTTTTA GTCCTCCGTG TTTCTCCTA AAACACCTCT GTTTTGCACT
30 GACCTGATGG GAAATAAATT ATATTAATT TTAAACCTT TCCGGTTGGA
TGCCTAACAT TTAGGCAAGA GACAACAAAG AAAACCAGAG TCAACTCCCT
TGAAATGTAG GAATAAAGGA TGCATAATAA ACAGGAAAGG CACAGGTTTT
GAGAAGATCA GCCCACAGTG TTGTCCCTGA ATCAAACAAA ATGGTCGGAG

GAACCCCTTCG GGTCAGCAC AAAGAGGTGA CTACAGCCTT TTGGTCACCA
GATGACTCCG CCCCTTGTA ATGAGTCTGC CAAGTAGACT CTATCAAGAT
TCTGGGGAAA GGAGAAAGAA CACATTGACC TGCCCGGGCG GCCGCTCGAG
CCCTATGA, disclosed as SEQ ID NO:17.

5

36. A purified DNA molecule encoding mouse uncoupling protein 3 wherein said DNA molecule encodes a protein consists of the amino acid sequence MVGLQPSEVP PTTVVKFLGA
GTAACFADLL TFPLDTAKVR LQIQGENPGA QSVQYRGVLG TILTMVRTEG
10 PRSPYSGLVA GLHRQMSFAS IRIGLYDSVK QFYTPKGADH SSVAIRILAG
CTTGAMAVTC AQPTDVVKVR FQAMIRLG TG GERKYRGTM D AYRTIAREEG
VRGLWKGTVWP NITRNAIVNC AEMVTYDIK EKLLESHLFT DNFPCCHFVSA
FGAGFCATVV ASPVDDVKTR YMNAPLGRYR SPLHCMK MV AQEGPTAFYK
15 GFVPSFLRLG AWNVMMFVTY EQLKRALMKV QVLRESPF*, as set forth in
three-letter abbreviation in SEQ ID NO:18.

37. A process for the expression of a mouse uncoupling protein 3 in a recombinant host cell, comprising:
20 (a) transfecting the expression vector of claim 23 into a suitable host cell; and,

25 (b) culturing the host cells of step (a) under conditions which allow expression of the human uncoupling protein 3 from the expression vector.

38. An expression vector for the expression of a mouse uncoupling protein 3 in a recombinant host cell wherein said expression vector comprises the DNA molecule of claim 35.

199591
39. A method of identifying a modulator of uncoupling protein 3 activity, which comprises:

5 (a) combining a modulator of uncoupling protein 3 activity with the uncoupling protein 3 or a biologically active fragment thereof; and,

(b) measuring the effect of the modulator on the activity of uncoupling protein 3.

10 40. The method of claim 39 wherein said uncoupling protein 3 is human uncoupling protein 3.

15 41. The method of claim 40 wherein said human uncoupling protein 3 is disclosed as SEQ ID NO:12.

42. The method of claim 39 wherein said uncoupling protein 3 is mouse uncoupling protein 3.

20 43. The method of claim 42 wherein said mouse uncoupling protein 3 is disclosed as SEQ ID NO:18.

44. A method of extending at least one partial cDNA sequence for the purpose of characterizing and isolating a full-length cDNA molecule, which comprises:

25 a) constructing a cDNA library in a DNA vector primed by random, oligo-dT or a combination of both random and oligo-dT primers;

30 b) subdividing the cDNA library into a plurality of cDNA pools, each of the cDNA pools containing from about 10,000 to about 20,000 cDNA molecules;

c) amplifying each cDNA pool;

- d) hybridizing oligonucleotide primers complementary to the 5' and 3' portion of the partial cDNA sequence and to the 5' and 3' flanking region of the DNA vector;
- 5 e) identifying each cDNA molecule which contains a flanking DNA fragment generated by PCR in each positive cDNA pool;
- f) sequencing the flanking DNA fragments; and,
- 10 g) assembling the partial cDNA sequence and the sequence from the flanking DNA fragment(s) into a complete open reading frame.

15

199591

TITLE OF THE INVENTION
HUMAN UNCOUPLING PROTEIN 3

5 ABSTRACT OF THE DISCLOSURE

An isolated nucleic acid molecule is disclosed which encodes a novel human uncoupling protein (UCP3), and related recombinant expression vectors, recombinant host cells and substantially purified forms of the UCP3 protein. The isolated nucleic acid and proteins disclosed herein will be useful in methods associated with identifying compounds which modulate energy expenditure and body weight regulation, as well as effecting diseases such as obesity and diabetes as well as mitochondria-associated hypermetabolism.

10 Additionally, the isolated nucleic acids of the present invention are candidates for gene therapy of a mammalian host, including humans.

15

20

Figure 1A

1 TCGAACTCAC TCAACCTCCCC TCTCACCTCA CTGCCCTCAC CAGCCAGCCT
 51 CTTGTCAAGT GATCAGGCTG TCAACCAACT TCTCTAGGAT AAGGTTTCAG
 101 GTCAGCCCTGT GTGTATAAGA CCAGTGCCTAA GCAGAGAAGCA GCAGAGACAA
 151 CAGTGAATGA CAAGGAGGGG CCATCCAATC CCTGCTGCCA CCTCCCTGGGA
 201 TGGAGCCCTA GGGAGCCCCCT GTGCTGCCCT TGCCGTGGCA GGACTCACAG
 251 CCCCCACCGCT GCACTGAAGC CCAGGGCTGT GGAGGCAGCTC TCTCCTTGGA
 301 CTCTCTCGG CCCTAAAGGG ACTGGGCAGA GCCTTCCAGG ACTATGGTTG
 351 GACTGAAGCC TTCAAGACGTG CCTCCCACCA TGGCTGTGAA GTTCCCTGGGG
 401 GCAGGCACAG CAGCCTGTTT TGCTGACCTC GTTACCTTTT CACTGGACAC
 451 AGCCAAGGTC CGCCTGCAGA TCCAGGGGGA GAACCAAGGGG GTCCAGACGG
 501 CCCGGCTCGT GCACTACCGT GGCCTGCTGG GCACCACTCT GACCATGGTG
 551 CGGACTGAGG GTCCCTGCAG CCCCTACAAAT GGGCTGGTGG CGGGCCTGCA
 601 GCGCCAGATG AGCTTCGCCT CCATCCGCAT CGGCCTTTAC GACTCCGTCA
 651 AGCAGGTGTA CACCCCCAAAG GGCAGGGACA ACTCCAGCCT CACTACCCGG
 701 ATTTTGGCGG GCTGCACCAAC AGGAGCCATG GGGGTGACCT GTGCCAGCC
 751 CACAGATGTG GTGAAGGTCC GATTTCAAGGC CAGCATACAC CTGGGGCCAT
 801 CCAGGAGCGA CAGAAAATAC AGCGGGACTA TGGACGCCTA CAGAACCATC
 851 GCCAGGGAGG AAGGAGTCAG GGGCCTGTGG AAAGGAACCTT TGCCCAACAT
 901 CATGAGGAAT GCTATCGTCA ACTGTGCTGA GGTGGTGACCC TACGACATCC
 951 TCAAGGAGAA GCTGCTGGAC TATCACCTGC TCACTGACAA CTTCCCTG
 1001 CACTTTGTCT CTGGCTTTGG AGCCGGCTTC TGTGCCACAG TGGTGGCCTC
 1051 CCCGGTGGAC GTGGTGAAGA CCCGGTATAT GAACTCACCT CCAGGGCAGT
 1101 ACTTCAGCCC CCTCGACTGT ATGATAAAAGA TGGTGGCCCA GGAGGGCCCC
 1151 ACAGCCTTCT ACAAGGGATT TACACCCCTCC TTTTTGGTGT TGGGATCCGT
 1201 GAAAGTGGTG ATGTTCGTAA CCTATGAGCA CCTGAAACGG GCGCTGATGA
 1251 AAGTCCAGAT GTTACGGGAA TCAACGTTTT GAAACAGACA AGAAGGCCAC
 1301 TGGTAGCTAA CGTGTCCGAA ACCAGTTAAG AATGGAAGAA AACGGTGCAT

Figure 1B

1351 CCACGGCACAC ATGGACACAG ACCCACACAT GTTTACAGAA CTGTTGTTA
 1401 CTTGTTGCTG ATTCAAGAAA CAGAAGTAGA AGAGAGAGGA TTCTGGCTTT
 1451 CACTGCCATG CCTCAAGAAC ACCTTTGTTT TGCAC TGACAA AGATGGAAAA
 1501 TAAATTATAT TAATTTTTGA AACCCATTAG GCATGCCTAA TATTTAGGCA
 1551 AGAGAAAATA AACCAAGATA GATCCATTG GACAAAATGG AAGGTTGGAG
 1601 ACGTGTATCC CCGTGAAATC TGGTCAGATA ATGAATGATA ACCAGGAAGG
 1651 ATGGCAAGCA CGGGACAGGA GGGGCCCCACA ATGGAGTGGG AGATCAGCCA
 1701 CGGAGCCTGG AGGGACGCCA CCCAGCAACA CAGAGCTGGC GACTGCAGCT
 1751 GCACCATCAC ACATGCATCA TCAGCCTATT TGTAATATGT CTGCCACAGA
 1801 GAGTCCTTG GGATTCTAGG AAACCCCAAGG AACAAAGAGAA AAAACTAGAG
 1851 CCTGTTGCTAA AGAAGCCTGC TGGGCCCCATG TGAGGCTGGG GTCGTAAATA
 1901 TTCCCCCGACG ACACTGAAGA ATCAAGAGGG CAGCCCCCAC TTCTCCTACA
 1951 AAATGGAGGG AGCCATCCCT TCCCTGTCCA CCTCACCAAGG GGTGCTATGA
 2001 CATGCAACTG AGAAGCTGGG CATGAACGCA CTTTATAAAA GCAAAAGCTC
 2051 TGTGTAATC TAATCTACAG GACAATGCCCT TGGGAGAGAT TTTGTCGGGA
 2101 CAGAGAGGAG TTGCCAGGGA AGAAGGTTTG AAAGATAACGG TTGTCTAGAG
 2151 GTGAGACCAA AGGATCCAGA GACTTGGGGA CCAGAGGTGA CAGTGGATGA
 2201 CGTGAAGCCA CAGGAGCCCC ACCCCCCATGC AGCTTTTCC CCACCCCCCCC
 2251 CACCAACGGGC TCAATCATGA GTACCTCAAA GGATTGTTGG GCTTGGGGGA
 2301 AAAGAGGTGG ATTCTGGGC AAAGAACCTAA AGTACCGAGGA (SEQ ID NO 11)

Figure 2A

1 TCGAATCACTCACTCCCTCTCACCTCACTCCCTCACCAAGCCAGCCCTTGTCAAGT 60
 1 AGCTTGACTGAGTGGAGGGAGAGTGGAGTGAAGGGAGTGGTCGGTCGGAGAACAGTTCA
 61 GATCAGGGCTCTCAACCAACTCTCTAGGATAAGGTTTCAAGGTCAAGCTCTGTGTATAAGA 120
 61 CTAGTCCGACAGTTGGTGAAGAGATCTTCAACAGTCCAGTCGGACACACATATTCT
 121 CCAGTGCCAAGCCAGAAGCAGCAGAGACAAACAGTGAATGACAAGGAAGGGCCATCCAATC 180
 121 GGTCAAGGTTGGTCTTCGTCGTCCTGTACTTACTCTCTCCCGTAGGTTAG
 181 CCTGGTGCACCTCTGGGATGGAGCCCTAGGGAGCCCTGTCCTGCCCCCTGGCA 240
 181 GGACGACGGTGGAGGACCCCTACCTGGGATCCCTGGGACACGGACGGGACGGCACCGT
 241 GGACTCACAGCCCCACGGCTGCACTGAAGGCCAGGGCTGTGGAGCAGCTCTCTCTGGGA 300
 241 CCTGAGTGTGGGGTGGCGACGTGACTTCGGGTCCTGACACCTCGTCGAGAGAGGAAACCT
 301 CTCTCTCGGCCCCCTAAAGGGACTGGGAGAGCCCTCCAGGACTATGGTTGGACTGAAAGCC 360
 301 GAGGAGAGCCGGATTTCCTGACCCGTCGGAAGGTCTGATACCAACCTGACTTCGG
 M V G L K P
 361 TTCAAGCTGCCCCCACCATGGCTGTGAAGTTCTGGGGGCAAGGCACAGCAGCCCTGTTT 420
 361 AAGCTCTGACGGAGGGTGGTACCGACACTCTCAAGGACCCCCCTCCGGTCGTCGGACAAA
 S D V P P T M A V K F L G A G T A A C F
 421 TGCTGACCTCGTTACCTTCCACTGGACACAGCCAAAGTCCGCTGCAAGATCCAGGGGA 480
 421 ACGACTGGAGCAATGAAAAGGTGACCTGTGTCGGTTCCAGGGAGCTAGGTCCCCCT
 A D L V T F P L D T A K V R L Q I Q G E
 481 GAACCAAGGCGTCCAGACGGCCGGCTCGTCAGTACCGTGGCTGCTGGGACCCATCCT 540
 481 CTGGTCCGCCAGGTCTGCCGGCCGAGCACGTATGGCACCGCACGACCCCTGCTAGGA
 N Q A V Q T A R L V Q Y R G V L G T I L
 541 GACCATGGTGGAGCTGAGGGTCCCTGCAAGCCCCCTACAAATGGCTGGTGGCCGGCTGCA 600
 541 CTGGTACCCACGCTGACTCCCAAGGGACGTGGGGATGTTACCCGACCCACGGCCGGACGT
 T M V R T E G P C S P Y N G L V A G L Q
 601 GCGCCAGATGAGCTTCCCTCCATCCCAATGGGCTTACGACTCCCTCAAGCAAGGTGA 660
 601 CGGGCTACTCGAACGGAGGTAGGGCTAGCCGGAAATGCTGAGGCAGTTCCTCCACAT
 R Q M S F A S I R I G L Y D S V K Q V Y
 661 CACCCCCAAAGGCGGACAACTCCAGCTCACTACCCGGATTTTGGCCCGCTGCACCAAC 720
 661 CTGGGGCTTTCGCGGCTGAGGTGGAGTGAAGGCTAAACCCGGCCGACGGTGGTG
 T P X G A D N S S L T T R I L A G C T T

Figure 2B

721 AGGAGCCATGGCGGTGACCTGTGCCAGGCCACAGATGTGGTGAGGTCCGATTTCAAGGC
 721+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 721 TCCCTGGTACCGCCACTGGACACGGGTCGGGTGTCTACACCACTTCCAGGCTAAAGTCCG
 721 G A M A V T C A Q P T D V V K V R F Q A
 781 CAGGATACACCTCGGGCCATCCAGGAGCGACAGAAAATACAGGGGACTATGGACGCCA
 781+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 781 GTCCTATGTGGAGCCCGGTAGGTCTCGCTGTCTTATGTGCGCCCTGATAACCTGCGGAT
 781 S I H L G P S R S D R K Y S G T M D A Y
 841 CAGAACCATGCCAGGGAGGAAGGAGTCAGGGGCTGTGGAAAGGAACCTTGCCAAACAT
 841+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 841 GTCCTGGTAGCGGTCCCTCTCTCTCAGTCCCCGGACACCTTCTCTTGAAACGGGTTGTA
 841 R T I A R E E G V R G L N X G T L P N I
 901 CATGAGGAATCTATCGTCAAATGTGCTGAGGTGGTGAACCTACGGACATCTCAAGGAGAA
 901+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 901 GTACTCTTACGATAGCAGTTGACACGACTCCACCACTGGATGCTGTAGGAGTTCTCTT
 901 M R N A I V N C A E V V T Y D I L K E K
 961 GCTGCTGGACTATCACCTGCTCACTGACAACCTTCCCTGCCACTTTGTCTCTGCTTTGG
 961+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 961 CGACGACCTGATAGTGGACGGACTGACTGTGAAGGGGACGGTGAACAGAGACGGAAAC
 961 L L D Y H L L T D N F P C H F V S A F G
 1021 AGCCGGCTCTGTGCCACAGTGGTGGCTCTCCCGGTGGACGTGGTGAAGACCCGGTATAT
 1021+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 1021 TCGGGCGAAGACACGGGTGCAACCEGGAGGGGCCACCTGCAACCACCTCTGGGCATATA
 1021 A G F C A T V V A S P V D V V K T R Y M
 1081 GAACTCACCTCCAGGCCAGTACTTCAGCCCCCTCGACTGTATGATAAAGATGGTGGCCCA
 1081+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 1081 CTTGAGTGGAGGTCCGGTCATGAAAGTCGGGGGAGCTGACATACTATTTCTACCACTGGG
 1081 N S P P G Q Y F S P L D C M I K M V A Q
 1141 GGAGGGCCCCACAGCCTTCTACAAGGGATTACACCCCTCTTGGGATCTG
 1141+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 1141 CCTCCCCGGGGTGTGGAAAGATGTTCCCTAAATGTGGGAGGAAACCGAAACCTAGGAC
 1141 E G P T A F Y K G F T P S F L R L G S W
 1201 GAACTGGTGAATGTTGTAACCTATGAGCAGCTGAAACGGGCTCTGATGAAAGTCCAGAT
 1201+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 1201 CTTGCAACCTACAAGCATGGATACTGTCGACTTGGCCCGGACTACTTTCAGGTCTA
 1201 N V V M F V T Y E Q L K R A L M K V Q M
 1261 GTTACGGAAATACCGTTTGAACAAGACAAGAAGGCCACTGGTAGCTAACGGTCCGGAA
 1261+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 1261 CAATCCCTTACTGGCAAACCTTCTCTGCTCTCCGGTACCTGGTACAGGCTT
 1261 L R E S P F * (SEQ 10 AC:12)
 1321 ACCAGTTAAGAAATGAAAGAAAACGGTACATCCACACACATGGACACAGACCCACACAT
 1321+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 1321 TGGTCAATTCTTACCTTCTTGGCACGTTAGGTGGTGTGTAACTGTGTCGGGTGTGTA

Figure 2C

1381	GTTCACAGAACTGTGTAACTTGTGCTGATTCAAGAAACAGAAGTAGAAGAGAGAGGA	1440
	CAAAATGTCTTGACAAACAAAATGAACAAACGACTAAGTTCTTGTCTTCATCTCTCTCCT	
1441	TTCGTGCTTCACTGCCATGCCCTCAAGAACACCTTGTGACTGACAAGATGGAAAA	1500
	AAGACCAGAAGTGACGGTACGGAGTTCTGTGAAACAAAACGTGACTGTCTACCTTTT	
1501	TAATATATTAATTTTGAAACCCATTAGGCATGCCATAATTAGGCAAGAGAAAAATA	1560
	ATTTAATATAATTAATTTGGTAATCCGTACGGATTATAAAATCCGTTCTCTTTAT	
1561	AAACCAAGATAGATCCATTGGACAAAATGGAAAGTTGGAGACGGTGTATCCCCGTGAAATC	1620
	TTGGTTCTATCTAGTAAACCTGTTTACCTTCCAACTCTGTGACATAGGGGCACTTTAG	
1621	TGGTCAGATAATGAAATGATAAGCAGGAAGGGATGGCAAGCACGGGACAGGGAGGGCCCCACA	1680
	ACCACTTATTACTTACTATTGTCCTTCCCTACCGTTGGTCCCTGTCCTCCCCGGGTGT	
1681	ATGGAGTGGGAGATCAGGCCACGGAGGCTGGAGGGACGCCACCCAGCAACACAGAGCTGGC	1740
	TACCTCACCCCTCTAGTCGGTCCCTGGACCTCCCTGCGGTGGGTGTTGTGTCTCGACCG	
1741	GAATGAGCTGCACCATCACACATGCATCATCAGCCTATTGTAAATATGTCTGCCACAGA	1800
	CTGACGTCGACGTGGTAGTGTGTACGTAGTACGGATAAAACATTATAACAGACGGTGTCT	
1801	GAATCTTGGGATTCTAGGAAAACCAAGGAACAAAGAGAAAAAACTAGAGCTCTGTCAA	1860
	CTCAGGAAACCTTAAGATCTTGGGTTCTTGTCTCTTTTTGATCTCGGACACGGATT	
1861	AGAACCTGCTGGGCCCATGTGAGGTGGGGTGTAAATATTCGGACGGACACTGAAGA	1920
	TCTTCGGACGCCGGGTACACTCCGACCCCAGCATTTATAAGGGCTGCTGTGACTTCT	
1921	ATCAAGAGGGCAGCCCCCACTTCTCTACAAAATGGAGGGAGCCATCCCTCCCTGTCCA	1980
	TAGTTCTCCCGTCGGGGGTGAAGAGGAATTTTACCTCCCTCGGTAGGGAGGGACAGGT	
1981	CTCAACCAAGGGTGTATGACATGCAAGTGTGAGAAGCTGGGATGAAACGGCACTTTATAAAA	2040
	GGAGTGGTCCCCACGGATACTGTACGTTACCTCCGACCCGTACTTGGCTGAAATATTTT	
2041	GGAAAAGCTTGTAAATCTAACTACAGGAACATGGCTGGGAGAGATTTTGTGGGA	2100
	CGTTTTCGAGACACATTAGATTGATGTTCTGTACCGAACCTCTCTAAACGGCCCT	
2101	CAGAGAGGAGTGGCAAGGGAGAAGGTTGGAAAGATAACGGTTCTAGAGGTGAGACCAA	2160
	GTCTCTCTCAACGGTCCCTCTCCAAACCTTCTATGCCAACAGATCTCCACTCTGGTT	
	AGGATCCAGAGACTTGGGACCAAGGGTGAACAGTGTGACGTGAACGCCACAGGGAGCCCC	

Figure 2D

Figure 3


1 MVGLKPSDVP PTMAVKFLGA GTAACFADLV TFPLDTAKVR LQIQGENQAV
51 QTARLVQYRG VLGTILTMVR TEGPCSPYNG LVAGLQRQMS FASIRIGLYD
101 SVKQVYTPKG ADNSSLLTRI LAGCTTGAMA VTCAQPTDVV KVRFQASIHL
151 GPSRSDRKYS GTMDAYRTIA REEGVRLWV GTLPNIMRNA IVNCAEVVTV
201 DILKEKLLDY HLLTDNFPCH FVSAFGAGFC ATVVASPVDV VKTRYMNSPP
251 GQYFSPLDCM IKMVAQEGPT AFYKGFTPSF LRLGSWNVVM FVTYEQLKRA
301 LMKVQMLRES FF* (SEQ 10 JUN. 12)

Northern Analysis of UCP3 Expression in Human Tissues

8/14
Figure 4

4A

UCP3
(13 hr. exp.)




- Pancreas
- Kidney
- Skeletal Muscle
- Liver
- Lung
- Placenta
- Brain
- Heart

MW(kb)

4B

UCP3
(0.5 hr exp.)




- Pancreas
- Kidney
- Skeletal Muscle
- Liver
- Lung
- Placenta
- Brain
- Heart

MW(kb)

4C

UCP3 and β -actin
(0.5 hr. exp.)



- Pancreas
- Kidney
- Skeletal Muscle
- Liver
- Lung
- Placenta
- Brain
- Heart

MW(kb)

9/14
FIGURE 5

9/14
FIGURE 5

3'EST ..
RA 192553

5' EST
AA192136

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

Diagram Key	
	Hole in contour
	Single fragment
	Multiple fragments same direction
	Both strands
	Both strands plus
	Start codon frame 1
	Start codon frame 2
	Stop codon frame 1
	Stop codon frame 2
	Bumps on fragments
	Show motifs
	Hollow rectangles
	Show features

1 CCAGGAACAG CAGAGACAAC AGTGAATGGT GAGGCCCGGC CGTCAGATCC
51 TGCTGCTACC TAATGGAGTG GATCCTTAGG GTGGCCCTGC ACTACCCAAC
101 CTTGGCTAGA CGCACAGCTT CCTCCCTGAA CTGAAGCAAA AGATTGCCAG
151 GCAAGCTCTC TCCTCGGACC TCCATAGGCA GCAAAGGAAC CAGGCCATT
201 CCCCCGGGACC ATGGTTGGAC TTCAGCCCTC CGAAAGTGCCT CCCACAAACGG
251 TTGTGAAGTT CCTGGGGGCC GGCACTGCCGG CCTGTTTGC GGACCTCCTC
301 ACTTTTCCCC TGGACACCGC CAAGGTCCGT CTGCAGATCC AAGGGGAGAA
351 CCCAGGGCT CAGAGCGTGC AGTACCGCGG TGTGCTGGGT ACCATCCTGA
401 CTATGGTGCG CACAGAGGGT CCCCCGAGCC CCTACAGCGG ACTGGTCGCT
451 GGCCTGCACC GCCAGATGAG TTTTGCCTCC ATTGAATTG GCCTCTACGA
501 CTCTGTCAAG CAGTTCTACA CCCCCAAGGG AGCGGACCAC TCCAGCGTCG
551 CCATCAGGAT TCTGGCAGGC TGCAAGACAG GAGCCATGGC AGTGACCTGC
601 GCCCAGGCCA CGGATGTGGT GAAGGTCCGA TTTCAAGCCA TGATACGCC
651 GGGAACTGGA GGAGAGAGGA AATACAGAGG GACTATGGAT GCCTACAGAA
701 CCATCGCCAG GGAGGAAGGA GTCAGGGCC TGTGGAAAGG GACTTGGCCC
751 AACATCACAA GAAATGCCAT TGTCAACTGT GCTGAGATGG TGACCTACGA
801 CATCATCAAG GAGAAGTTGC TGGAGTCTCA CCTGTTTACT GACAACCTCC
851 CCTGTCACTT TGTCTCTGCC TTTGGAGCTG GCTTCTGTGC CACAGTGGTG
901 GCCTCCCCGG TGGATGTGGT AAAGACCCGA TACATGAACG CTCCCCTAGG
951 CAGGTACCGC AGCCCTCTGC ACTGTATGCT GAAGATGGTG GCTCAGGAGG

FIGURE 6A

1001 GACCCACGGC CTTCTACAAA GGATTTGTGC CCTCCTTCT GCGTCTGGGA
1051 GCTTGGAACG TGATGATGTT TGTAACATAT GAGCAACTGA AGAGGGCCTT
1101 AATGAAAGTC CAGGTACTGC GGGAAATCTCC GTTTGAACA AGGCAAGCAG
1151 GCTGCCTGGA ACAGAACAAA GCGTCTCTGC CCTGGGGACA CAGGCCACA
1201 CGGTCCAGAA CCCTGCACTG CTGCTGACAC GAGAAACTGA ACTAAAAGAG
1251 GAGAGTTTTA GTCCTCCGTG TTTCGTCCTA AAACACCTCT GTTTGCACT
1301 GACCTGATGG GAAATAAATT ATATTAATT TTAAACCCCTT TCCGGTTGGA
1351 TGCCTAACAT TTAGGCAAGA GACAACAAAG AAAACCAGAG TCAACTCCCT
1401 TGAAATGTAG GAATAAAGGA TGCATAATAA ACAGGAAAGG CACAGGTTTT
1451 GAGAAGATCA GCCCACAGTG TTGTCCTTGA ATCAAACAAA ATGGTCGGAG
1501 GAACCCCTTCG GGTTCAGCAC AAAGAGGTGA CTACAGCCTT TTGGTCACCA
1551 GATGACTCCG CCCCTTTGTA ATGAGTCTGC CAAGTAGACT CTATCAAGAT
1601 TCTGGGGAAA GGAGAAAGAA CACATTGACC TGCCCGGGCG GCCGCTCGAG
1651 CCCTATGA (SEQ ID NO:17)

FIGURE 6B

1 MVGLQPSEVP PTTVVKFLGA GTAACFADLL TFPLDTAKVR LQIQGENPGA
51 QSVQYRGVLG TILTMVRTEG PRSPYSGLVA GLHRQMSFAS IRIGLYDSVK
101 QFYTPKGADH SSVAIRILAG CTTGAMAVTC AQPTDVVKVR FQAMIRLG TG
151 GERKYRGTM D AYRTIAREEG VRGLWKGTWP NITRNAIVNC AEMVTYDI IK
201 EKLLESHLFT DNFPCHFVSA FGAGFCATVV ASPVDVVKTR YMNAPLGRYR
251 SPLHCMVKMV AQEGPTAFYK GFVPSFLRLG AWNVMMFVTY EQLKRALMKV
301 QVLRESPF* (SEQ ID NO:18)

FIGURE 7




FIGURE 8A




FIGURE 8B




FIGURE 8C




FIGURE 9A




FIGURE 9B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
DECLARATION AND POWER OF ATTORNEY

Assistant Commissioner for Patents
 Washington, D.C. 20231

As a below-named inventor, I hereby declare that I believe I am:

the original, first and sole inventor; or

an original, first and joint inventor along with the other inventors listed below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

HUMAN UNCOUPLING PROTEIN 3

the specification of which is attached hereto;

was filed on _____ as Application

Serial No. _____ and was amended

through _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended as indicated above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

Foreign Priority

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate for the same invention having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

Country	Number	Date Filed	Attorney Docket

Yes No

Country	Number	Date Filed	Attorney Docket

Yes No

Prior United States Filing

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

60/047,179	May 20, 1997	19959PV
Appln. Ser. No.	Filing Date	Attorney Docket
60/069,141	December 9, 1997	19959PV2
Appln. Ser. No.	Filing Date	Attorney Docket
Appln. Ser. No.	Filing Date	Attorney Docket
Appln. Ser. No.	Filing Date	Attorney Docket

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

Appln. Ser. No.	Filing Date	Status	Attorney Docket
Appln. Ser. No.	Filing Date	Status	Attorney Docket
Appln. Ser. No.	Filing Date	Status	Attorney Docket
Appln. Ser. No.	Filing Date	Status	Attorney Docket
Appln. Ser. No.	Filing Date	Status	Attorney Docket
Appln. Ser. No.	Filing Date	Status	Attorney Docket
Appln. Ser. No.	Filing Date	Status	Attorney Docket

And I hereby appoint

J. MARK HAND

JACK L. TRIBBLE

Reg. No. 36,545

Reg. No. 32,633

Reg. No. _____

respectively and individually, as my attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

J. MARK HAND

Patent Department
Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907

Telephone No. (732) 594- 3905

I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or joint inventor	QINGYUN LIU
Inventor's Signature	
Date	
Residence	North Wales, PA 19454
Citizenship	China
Post Office Address (if different from above)	P.O. Box 2000 Rahway, N.J. 07065

Full name of joint inventor	FANG CHEN
Inventor's Signature	
Date	
Residence	North Wales, PA 19454
Citizenship	U.S.
Post Office Address (if different from above)	P.O. Box 2000 Rahway, N.J. 07065

Full name of joint inventor	
Inventor's Signature	
Date	
Residence	
Citizenship	
Post Office Address (if different from above)	

Full name of joint inventor	
Inventor's Signature	
Date	
Residence	
Citizenship	
Post Office Address (if different from above)	